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ABSTRACT OF THE DISSERTATION 
Investigations into Building Block Structure and Method of Preparation on the Properties of 
Nanomaterials 
 
By 
Zicheng Li 
Doctor of Philosophy in Chemistry 
Washington University in Saint Louis, 2009 
Professor Karen L. Wooley, Chairperson 
 
 This dissertation research is primarily focused on the preparation of polymer-based 
nanostructures as potential diagnostic agents and therapeutics delivery vehicles.  Various polymers, 
nanoparticles and conjugation techniques were developed to meet the specific requirements of each 
application. 
Shell crosslinked nanoparticles (SCKs) are characterized by their structural integrity and 
available functionality to attach multiple agents on the shell, such as receptor-recognizing or 
receptor-specific ligands, .imaging agents, Cell transduction components, etc.  In this work, SCKs 
derived from amphiphilic poly(acrylic acid)-block-polystyrene (PAA-b-PS) have been studied as 
potential diagnostic and therapeutic agent delivery vehicles (Chapters 2 and 4).  SCK nanoparticles 
bearing a cyclic KCRGDC peptide which specifically binds to αvβ3 integrin receptor were developed 
as potential delivery system for treatment of acute vascular injuries.  Methods were developed to 
 iii
afford “clean” nanoparticles with significant binding abilities.  Nanoscale contrast agents for 
magnetic resonance imaging were also developed based on SCKs derived from PAA-b-PS and a 
Gadolinium-DOTA complex to achieve high relaxivity contrast agents.  Our results showed that 
SCKs may serve well as potential diagnostic and therapeutic agent delivery vehicles  Meanwhile, 
these SCKs were also studied as the template for mineralization of silver nanoparticles, along with a 
nuleating peptide, AG-P35, as a co-template (Chapter 5).  Various morphologies of silver 
nanoparticles were obtained and it’s found that the morphology was highly dependent on polymer and 
peptide concentrations and incubation time. 
Micelles from a novel hyperbranched fluoropolymer with small sizes able to pass the blood brain 
barrier were synthesized (Chapter 3).  After conjugation with F3 peptide which targets to nucleolin in 
most tumor cells, and loaded with doxorubicin as the drug to kill the tumor cells, both in vitro and in 
vivo studies were performed.  It was found that F3-peptide conjugated nanoparticle not only 
specifically bind to the tumor-associated angiogenic endothelial cells, doxorubicin carried by these 
nanoparticles also caused apoptotic effects on the targeted tumor cells. 
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Chapter 1 
 
Introduction 
 
Nanotechnologies are materials and devices that have a functional organization in at 
least one dimension on the nanometer scale, ranging from a few to about 100 
nanometers.1  Nature has given us numerous examples of building complex 
supramolecular structures using nanoscale objects to achieve a variety of efficient 
functions.  Metallo-porphyrins, a class of small molecules that are involved in the 
photosynthesis of plants, have sizes around 1 nm; DNA, the material containing all the 
genetic information of life, has a size around 2 nm; proteins have size around 10 nm.  
The essence of chemical science finds its full expression in the words of that epitome of 
the artist-scientist Leonardo da Vinci: “Where Nature finishes producing its own species, 
man begins, using natural things and with the help of this nature, to create an infinity of 
species”.2  The elegance of nature in building complex structure has stimulated many 
scientists to construct man-made materials and devices that mimic nature, and with 
potential for sensing, catalysis, transport, and other applications in medicinal or 
engineering science.3-9  Unique properties were found not only in inorganic 
nanomaterials, but also in organic/polymeric nanomaterials.  The discovery of crown 
ether,10, 11 and the subsequent studies in designing more complex cyclic molecules to 
1
 
 
recognize positive ions are the first demonstrations of man-made organic materials that 
can self-assemble into complex structures, known as host-guest chemistry12 or 
supramolecular chemistry13, and the size of the building blocks is at the molecular level 
(less than 2 nm). 
Self-assembly, defined as “the autonomous organization of components into patterns 
or structures without human intervention”,14 is a very common process occurring in 
nature, such as the self-assembly of amphiphilic poly-peptides into proteins with complex 
supramolecular structures and functionalities and biomineralization processes.15  
Inspired by this, material mimics have been synthesized using natural or unnatural 
building blocks to form supramolecular assemblies with unique optical, electric, catalytic 
and biological properties, such as synthetic polypeptide,16 peptides amphiphiles,17 giant 
amphiphiles,18 DNA assemblies,19 and synthetic oligomers or polymers.20, 21 
Amphiphilic block copolymers are among the synthetic amphiphiles for the 
construction of supramolecular assemblies.22  The self-assembly of amphiphilic block 
copolymers can generate a variety of morphologies, such as spheres, rod, vesicles, 
lamellas and toroids,23 which offers a broad selection of building blocks for the 
construction of nanostructured materials as well as their use in biomedical applications.24 
Since its first development for drug delivery purposes and for vaccines in the late 
1960s,25 nanoparticles for pharmaceutical and medical application were studied 
intensively, taking advantage of the enhanced permeability and retention effect (EPR 
2
 
 
effect).26-28  Nanoparticles were demonstrated to be able to improve the delivery of 
anticancer drugs,29 antiinfective drugs,30-32 as well as nucleic acids, DNA fragments and 
genes,33-35 and for the treatment of AIDS.36, 37  Among all these, the most important 
application of nanoparticles is considered to be their employment for cancer therapy. 
Current cancer therapy usually involves intrusive processes including application of 
catheters to allow chemotherapy, initial chemotherapy to shrink any cancer present, 
surgery to then remove the tumor(s) if possible, followed by more chemotherapy and 
radiation.  The purpose of the chemotherapy and radiation is to kill the tumor cells as 
these cells are more susceptible to the actions of these drugs and methods because of their 
growth at a much faster rate than healthy cells, at least in adults.38  Current research 
areas include development of carriers to allow alternative dosing routes, new therapeutics 
targeting blood vessels fueling tumor growth and targeted therapeutics that are more 
specific in their activity.  In all cases, the effectiveness of the treatment is directly 
related to the treatment’s ability to target and to kill the cancer cells while affecting as 
few healthy cells as possible.  Nanoparticles will usually be taken up by the liver, spleen 
and other parts of the reticuloendothelial system (RES) mainly depending on their surface 
characteristics.39, 40  Usually, particles with long circulation times, and hence greater 
ability to target to the site of interest, should be 100 nm or less in diameter and have a 
hydrophilic surface in order to reduce clearance by macrophages.41  Angiogenesis is a 
physiological process involving the growth of new blood vessels from existing 
3
 
 
vasculature,42 and is especially vital to the continued development of a tumor mass from 
a dormant state to a malignant one.43-45  Angiogenesis is a multi-step, invasive process, 
characterized by endothelial cell proliferation, modulation of the extracellular matrix 
(ECM), and cell adhesion/migration.  Among the many angiogenic factors, integrin αvβ3 
has been found to be necessary for the formation, survival, and maturation of new blood 
vessels.46  The tripeptide sequence arginine-glycine-aspartic acid (RGD) is common to 
various ECM proteins, e.g. vitronectin, fibronectin, fibrinogen, thrombospondin, and 
von-Willebrand factor, involved in cell-matrix adhesion.47, 48  High-affinity αvβ3 
selective ligands containing RGD have been identified by phage display.49  Targeted 
chemotherapy has been investigated using RGD peptides to deliver doxorubicin50 and 
proapoptotic peptides51 to tumor vasculature.  In vivo imaging of sites of angiogenesis 
has been demonstrated using RGD-containing peptides.52, 53  Since the RGD-sequence is 
conserved in all native ligands, differences in binding affinities and specificity can be 
obtained from slight modifications of the peripheral structure of the RGD motif.  The 
flanking amino acid residues, especially the two positions following the aspartic acid, are 
known to change binding affinity both by direct interaction of the residues with the 
integrin as well as influencing peptide folding.54  Cyclization is a common technique to 
improve binding properties because it confers rigidity on the structure.55  All selective 
RGD peptides have at least one ring structure.  Linear RGD peptides are highly 
susceptible to degradation, due to reaction of the aspartic acid residue with the peptide 
4
 
 
backbone.56  Non-natural peptide modifications, such as the introduction of D-amino 
acids and replacement with peptidomimetic structures, have yielded RGD peptide ligands 
with greater specificity and nanomolar or higher affinities.57  Multivalent RGD-protein 
conjugates demonstrate subnanomolar affinity for αvβ3-expressing human umbilical vein 
endothelial cells (HUVEC), a 250-fold increase verses the monomer.58  Furthermore, 
multivalency has been shown to facilitate internalization.59  Carrier systems like 
liposomes, nanoparticles, and proteins bearing multiple RGD peptides are, therefore, 
more likely to be internalized via receptor-mediated endocytosis than single peptide 
constructs. 
Shell cross-linked nanoparticles (SCKs), a class of well-defined, polymeric, 
nanostructured materials, constitute a unique class of materials with amphiphilic 
core-shell morphology.60-62  SCKs are characterized by their structural integrity and 
available functionality to attach receptor-recognizing or receptor-specific ligands on the 
shell.  Studies have been reported on incorporating bioactive molecules, such as biotin 
and folate, for imaging and radiotherapy purposes.63, 64 
In this dissertation work, SCKs prepared from the amphiphilic block copolymer, 
poly(acrylic acid)-b-polystyrene (PAA-b-PS) have been selected as the carrier for a 
cyclic peptide KCRGDC, to act as the nano-agent to target αvβ3 integrin receptors for 
treatment of acute vascular injuries (Chapter 2).  These SCKs were functionalized with 
poly(ethylene glycol) (PEG) as a means to achieve prolonged blood retention time.  
5
 
 
DOTAlysine (a derivative of DOTA, 
1,4,7,10-tetraazacyclodecane-N,N’,N”,N”’-tetraacetic acid, with a lysine arm attached, 
chemical structure available in Chapter 2) was also labeled onto the SCKs as the chelator 
for radionuclide for position emission tomography (PET) imaging.  Methods have been 
developed to afford clean RGD-labeled SCKs (in terms of contamination of free 
KCRGDC peptide) with significantly enhanced in αvβ3.  Cell internalization studies 
with U87MG glioma cells showed significant internalization of these RGD-labeled 
nanoparticles. 
One of the most promising applications of nanoparticles is their use for the transport 
of drugs across the blood-brain barrier (BBB).  The central nervous system (CNS) is the 
most common site of primary solid tumors in children.65-68  Glioblastoma multiforme 
(GBM) is a highly malignant tumor in central nerve system.69, 70  Patients diagnosed 
with GBM usually live less than one year after surgery despite intensive chemotherapy 
and radiation.71  One of the biggest challenges for treating these patients is lack of 
effective therapeutics that could efficiently pass BBB and specifically target to the tumor 
site.72-75  It’s reported that nanoparticles with certain targeting ligands can gain access in 
the brain via a number of possible mechanisms, such as adsorption, receptor mediated 
endocytosis, transcytosis, membrane permeabilization effect, or disrupting the BBB.76.  
In Chapter 3, micelles from a novel star-like amphiphilic fluorinated block copolymer77 
with hydrodynamic diameters around 30 nm have been conjugated with an F3 peptide 
6
 
 
(specifically targets to nucleolin) and loaded with doxorubicin as the drug to treat tumor 
cells in the brain of U87MG xenograft mice.  Specific targeting to U87MG glioma cells 
were observed for these micelles.  In vivo studies with U87MG mice indicated the 
ability of these micelles to cross the BBB.  It was found that F3-peptide conjugated 
nanoparticle not only specifically bind to the tumor-associated angiogenic endothelial 
cells, doxorubicin carried by these nanoparticles also caused apoptotic effects on the 
targeted tumor cells.  PEGylation was found to enhance the biodistribution of these 
materials by affording an improved blood retention time.  This system showed potential 
to not only provide a novel approach to efficiently deliver therapeutics to the targeted 
tumor site, it can also potentially attenuate systemic side effects caused by free 
doxorubicin. 
Besides targeting and therapeutic agents, imaging modalities such as contrast agents 
for magnetic resonance imaging (MRI) were also labeled to PAA-b-PS based SCKs.  
MRI measures the NMR signals of nuclei, mainly protons of water.  The differences in signal 
intensity can create contrast in the images, thereby enabling differentiation of the types of tissues 
and detection of disease states.78  MRI has been advanced by the development of contrast agents 
that enable more specific and clearer images and enlargements of detectable organs and systems, 
leading to a wide scope of applications of MRI not only for diagnostic radiology but also for 
therapeutic medicine.79  The ability of the contrast agent to enhance the longitudinal relaxation 
rate (1/T1) of the solvent (mostly water) is referred to as the longitudinal relaxivity, R.  Current 
7
 
 
T1 MRI contrast agents are mainly in the form of paramagnetic metal complexes.80  A common 
approach to enhance the T1 relaxivities is to attach the complex to slow tumbling 
macromolecules.81  In Chapter 4, gadolinium (Gd) based nanoscale CAs were developed 
from attaching the complex of Gd with DOTAlysine to achieved enhanced relaxivities.  
Methods have been developed to afford nanoparticles without the highly toxic free Gd3+ 
ions.  The results indicated enhanced relaxivities compared to the small 
Gd-DOTAlysine complex.  It is found that T1 relaxivities increased as the extent of 
crosslinking of the micelles increased.  With the good blood pool imaging capabilities, and 
potential for active targeting (as described in previous chapters), as well as the enhanced T1 
relaxivities, SCKs have the potential to serve as a promising candidate for in vivo MRI imaging. 
In this work, SCK nanoparticles were also studied as the template for the growth of 
silver nanoparticles.  Because of their intriguing optical, electronic, magnetic and 
mechanical properties,82-85 silver nanoparticles have been intensively studied.  
Controlling the size of nanocrystals is of particular interest because of the effect these 
parameters have on the observed properties of the nanocrystals.  Various 
macromolecules and their assemblies, such as viruses and proteins, polymers, porous 
polymer matrices, microemulsions, starch vermicelli and cellulose, have been studied as 
templates to grow inorganic nanoparticles.86-90  Synthetic peptides binding to certain 
faces of inorganic nanocrystals are also being developed to direct the growth of inorganic 
nanoparticles.91, 92  In Chapter 5, SCKs prepared from poly(acrylic acid)-b-poly(methyl 
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acrylate) and peptide AG-35 (binds to (111) of silver) were studied as the template to 
grow silver nanoparticles.  Silver nanospheres, nanoplates, nano-flowers were obtained 
under varied conditions. 
 
. 
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Chapter 2 
 
RGD-conjugated Shell Crosslinked Nanoparticles (RGD-SCKs) for αvβ3 
Binding Affinity Studies 
 
Abstract 
 In this work, micelles and shell crosslinked nanoparticles (SCKs), prepared from 
poly(acrylic acid)-b-polystyrene block copolymer precursors, were functionalized with 
the cyclic peptide KCRGDC to generate nanoscale agents for targeted imaging and drug 
delivery.  The peptide contained a tripeptide arginine-glycine-aspartic acid (RGD) 
sequence as the recognition motif for the αvβ3 integrin receptor, which is highly 
expressed in tumors, cardiovascular sites, and other areas where angiogenesis occurs.  
Our specific interest in these nanomaterials includes their development as agents for the 
selective imaging and treatment of acute vascular injury.  The work within this chapter 
focuses upon rigorous studies to develop methods for the synthesis of nanoparticles 
functionalized with covalently-attached and ready-to-bind KCRGDC peptides.  Special 
attention is paid to the need for the peptides to be presented from the surface of the 
nanoparticles and to be available for binding with their protein receptors.  The binding 
affinities of these peptide-labeled nanoparticles were, therefore, evaluated by means of 
IC50 values to αvβ3, and those data were used to guide the synthetic efforts further.  
Targeting to the αvβ3 integrin, with selectivity against other integrins such as αvβ5, was 
also demonstrated.  The best affinities to αvβ3 receptors was achieved by 
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post-conjugation strategy that involved pre-assembly of nanostructures functionalized 
with reactive groups on the ends of grafted poly(ethylene glycol) (PEG) chains followed 
by attaching the KCRGDC peptide, with the highest affinity being observed for 
nanoscopic polymer micelles assembled from 
HOOC-PEG30004-g-DOTAlysine3.2-g-PAA58.8-b-PS71, which gave an IC50 value of 0.49 
nM.  Compared with the unconjugated KCRGDC peptide having an IC50 value of 10.5 
nM to αvβ3, the RGD-nanoparticles exhibited a considerable binding affinity 
enhancement of ca. 20-fold.  Also, a pre-conjugation strategy was explored, which 
involved the attachment of the KCRGDC peptide to the block graft copolymer prior to 
micellar assembly, but this approach seemed to allow for inward folding of the grafted 
chains and burying of peptides within the inner portions of the nanoparticles, giving 
lower binding affinities to  αvβ3.  Interest in these materials also for cancer imaging 
and therapeutic delivery was explored, from which in vitro cell assay experiments 
demonstrated significant binding and internalization of these nanoparticles with a glioma 
cell line. 
23
Introduction 
Angiogenesis is a physiological process involving the growth of new blood vessels 
from existing vasculature.1  It is a normal process involved in many biological processes, 
e.g. embryogenesis, wound healing, and tissue remodeling.  It is also a fundamental step 
in the transition of tumors from a dormant state to a malignant one.  Several disorders 
are characterized by either an excess or insufficient number of blood vessels, e.g. 
rheumatoid arthritis2, psoriasis3, restenosis4, and diabetic retinopathy5. 
Being essential for the proliferation and metastatic properties of human tumors, 
angiogenesis is a multi-step and invasive process, as characterized by the endothelial cell 
proliferation, the modulation of extracellular matrix (ECM), and the cell 
adhesion/migration.  Among the many angiogenic factors, integrin αvβ3 has been found 
to be necessary for the formation, survival, and maturation of new blood vessels.6  In 
human melanoma cells, the expression of αvβ3 is correlated with malignancy grade, 
collagenase production, and cell growth.7, 8  Due to the key roles of integrin αvβ3 in 
many physiological processes, it has been evaluated extensively as target.  The 
tripeptide sequence arginine-glycine-aspartic acid (RGD) is common to various ECM 
proteins, e.g. vitronectin, fibronectin, fibrinogen, thrombospondin, and von-Willebrand 
factor, involved in cell-matrix adhesion.9, 10  High-affinity αvβ3 selective ligands 
containing RGD have been identified by phage display.11  Targeted chemotherapy has 
been investigated using RGD peptides to deliver doxorubicin12 and proapoptotic 
peptides13 to tumor vasculatures.  In vivo imaging of sites of angiogenesis has been 
demonstrated using RGD-containing peptides.14, 15 
Although the RGD-sequence is conserved in all native ligands, slight modifications 
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still can provide differences in both binding affinities and specificities.  The flanking 
amino acid residues, especially the two positions following the aspartic acid, are known 
to change binding affinity by direct interaction of the residues with the integrin as well as 
influencing the peptide folding.9  Cyclization is a common technique to improve binding 
properties because it confers rigidity on the structure.16  All selective RGD peptides 
have at least one ring moiety.  It has been recently reported that multimeric RGD 
peptides could enhance the binding affinity of receptor-ligand interactions through either 
multivalent binding or statistical rebinding.  Polyvalency affords better targeting 
capability and higher cellular uptake because of the increased apparent ligand 
concentration.17  The unique structural properties of nanoscale materials provide the 
ability for them to carry therapeutic agents and to present numerous targeting moieties as 
well.  Furthermore, multivalency has been shown to facilitate internalization.18  Carrier 
systems like liposomes,19 polymers,20-22 nanoparticles,23 and proteins24 bearing multiple 
RGD peptides are, therefore, more likely to be internalized via receptor-mediated 
endocytosis than single peptide constructs. 
In this work, the cyclic KCRGDC peptide was selected as the antagonist to αvβ3.  
Shell crosslinked nanoparticles (SCKs) were used as the carrier system.  SCKs are 
self-assembled core-shell nanomaterials, originating from the crosslinking of the shell 
domain of micelles assembled from amphiphilic block copolymers (poly(acrylic 
acid)-b-polystyrene (PAA-b-PS) in this work).  The SCKs obtained have a robust 
structure due to the covalent crosslinking reaction, and have controllable sizes ranging 
from 10 to 200 nm.25, 26  SCKs conjugated with KCRGDC peptide were synthesized via 
various methods and were tested for binding affinities to αvβ3 via in vitro plate-based 
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assays (in collaboration with A. L. Fiamengo and C. J. Anderson).  Improved binding 
affinities were achieved, compared to the KCRGDC peptide as a small molecule that is 
capable only of monovalent binding.  KCRGDC-conjugated SCKs also showed good 
binding and internalization to U87MG glioma cells (studied in collaboration with Z. Xu 
and J. R. Leonard).  Such particles were found to be both non-toxic to mammalian cells 
and non-immunogenic within mice.  With the enhanced blood circulation times that can 
be achieved by grafting poly(ethylene glycol) from the nanoparticles,27 these 
multi-functional materials could be good candidates as carrier systems for imaging and 
therapeutic agents, selectively to injured or diseased tissues that overexpress αvβ3. 
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Experimental Section 
Materials 
All solvents were purchased from Sigma-Aldrich and used without further 
purification unless otherwise noted.  Trifluoroacetic acid (TFA; 95%; Aldrich), 
2,2′-(ethylenedioxy)-bis(ethylamine) (97%; Aldrich), 
1-(3′-dimethylaminopropyl)-3-ethylcarbo-diimide methiodide (EDCI; 98%; Aldrich), 
N-hydroxysuccinimide (NHS; 98%; Aldrich), N-Hydroxysulfosuccinimide sodium salt 
(sulfo-NHS; 98.5%; Aldrich), N,N′-Dicyclohexylcarbodiimide (DCC; 99%; Aldrich), 
Succinic anhydride (99%; Aldrich), were used as received.  Supor 25 mm 0.1 μm 
Spectra/Por Membrane tubes (molecular weight cutoff (MWCO) 3,500 or 6-8000 Da), 
purchased from Spectrum Medical Industries Inc., were used for dialysis.  Sodium 
phosphate monobasic (>99.0%), sodium phosphate dibasic (>99.0%), sodium chloride 
(>99.0%) were purchased from Sigma-Aldrich.  Precursor of DOTAlysine was a gift 
from Dr. Dennis A. Moore at Covidien Inc., Saint Louis, MO.  Nanopure water (18 
MΩ⋅cm) was acquired by means of a Milli-Q water filtration system (Millipore Corp.; 
Bedford, MA).  KCRGDC was custom synthesized by Tianma Pharma Co., Suzhou, 
China, and used as received.  5-FAM-KCRGDC was custom synthesized by Chengdu 
Kaijie Biopharmaceuticals Co. Ltd., Chengdu, China, and was used as received.  
Polyethylene glycol (PEG) and derivatives were purchased from Rapp Polymere GmbH, 
Germany, and used as received.  Superfine Sephadex ® G75 resin (bead diameter: 20-50 
μm; Fractionation range: 1000-50000 Da (Dextrans)) was purchased from GE Healthcare 
and was used to purify aqueous nanoparticle samples.   
5 mM PBS (phosphate buffered saline, with 5 mM of phosphates and 5 mM of NaCl) 
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was prepared by mixing NaH2PO4 (0.76 g), Na2HPO4 (1.93 g) and NaCl (1.17 g) into 4 
liters of nanopure water and was used as the solvent for dialysis.  150 mM PBS 
(phosphate buffered saline, with 150 mM of phosphates and 150 mM of NaCl) was 
prepared by mixing NaH2PO4 (22.7 g), Na2HPO4 (59.0 g) and NaCl (35.1 g) into 4 liters 
of nanopure water and was used as the solvent for running Sephadex ® columns.  Both 
buffers have pH values around 7.4. 
PAA61-b-PS34 and SCKs assembled from PAA61-b-PS34 were prepared as reported via 
atom transfer radical polymerization (ATRP).28  PAA64-b-PS54 and its derivatives 
functionalized with NH2-PEO113-OCH3 and DOTAlysine were prepared by Dr. Guorong 
Sun.27  DOTAlysine2.5-g-PAA68-b-PS70, which was synthesized via ATRP, was provided 
by Dr. Jinqi Xu.28  PAA66-b-PS71 was synthesized by Dr. Andreas Nyström via 
reversible addition-fragmentation chain transfer polymerization (RAFT).34 
Instrumental 
1H NMR spectra were recorded on a Varian 300 MHz spectrometer interfaced to a 
UNIX computer using Mercury software.  Chemical shifts are referred to the solvent 
proton resonance. 
Transmission electron microscopy (TEM) was performed in bright-field mode with a 
JEOL 2000-FX at 150 kV accelerating voltage.  Samples for TEM measurements were 
diluted with 1 wt% of phosphotungstic acid (PTA) stain solution (v/v, 1:1).  Carbon 
grids were exposed to oxygen plasma treatment to increase the surface hydrophilicity.  
Micrographs were collected at 100,000 magnifications.  The number average particle 
diameters (Dav) and standard deviations were generated from the analysis of a minimum 
of 150 particles from at least three different micrographs. 
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The average heights for the nanoparticles were determined by performing 
tapping-mode AFM under ambient conditions in air.  The AFM instrumentation 
consisted of a Nanoscope III BioScope system (Digital Instruments, Veeco Metrology 
Group; Santa Barbara, CA) and standard silicon tips (type, OTESPA-70; L, 160 μm; 
normal spring constant, 50 N/m; resonance frequency, 246-282 kHz).  Samples for AFM 
imaging analysis were prepared through spin-coating ca. 2.0 μL of the nanoparticle 
solution (typical concentration: 0.2 mg/mL) onto freshly cleaved mica plates (Ruby clear 
mica, New York Mica Co.) and allowed to dry freely in air.  The number-average 
particle heights (Hav) values and standard deviations were generated from the sectional 
analysis of more than 150 particles from several different regions. 
Hydrodynamic diameters (Dh) and size distributions for the SCKs in aqueous 
solutions were determined by dynamic light scattering (DLS).  The DLS instrument 
consisted of a Brookhaven Instruments Limited (Worcestershire, U.K.) system, including 
a model BI-200SM goniometer, a model BI-9000AT digital correlator, a model EMI-9865 
photomultiplier, and a model 95-2 Ar ion laser (Lexel Corp., Farmindale, NY) operated at 
514.5 nm.  Measurements were made at 20 °C.  Prior to analysis, solutions were 
filtered through a 0.22 μm Millex GV PVDF membrane filter (Millipore Corp., Medford, 
MA) and then centrifuged in a model 5414 microfuge (Brinkman Instruments, Inc., 
Westbury, NY) for 10 minutes to remove dust particles.  Scattered light was collected at 
a fixed angle of 90 °.  The digital correlator was operated with 522 ratio spaced channels, 
and initial delay of 5 μs, a final delay of 100 ms, and a duration of 10 minutes.  A 
photomultiplier aperture of 400 μm was used, and the incident laser intensity was 
adjusted to obtain a photon counting of between 200 and 300 kcps.  Only measurements 
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in which the measured and calculated baselines of the intensity autocorrelation function 
agreed to within 0.1% were used to calculate particle sizes.  The calculations of the 
particle size distributions and distribution averages were performed with the ISDA 
software package (Brookhaven Instruments Company), which employed 
single-exponential fitting, cumulants analysis, non-negatively constrained least-squares 
(NNLS) and CONTIN particle size distribution analysis routines.  All determinations 
were made in triplicate. 
Fast protein liquid chromatography (FPLC) was performed by Dr. Yongjian Liu in 
Prof. Michael J. Welch’s laboratory at Washington University School of Medicine on an 
AKTA (GE) system, including a P-920 pump, Columns of Superose 12 10/300 GL, and a 
UV detector with 254 nm wavelength.  The eluent was 20 mM HEPES with 150 mM 
NaCl and flow rate was 0.8 mL/min.  The results were analyzed by UNICORN 3.10.11. 
UV-vis spectra were acquired on a Varian Cary 1E UV-vis system (Varian, Inc., Palo 
Alto, CA) using polystyrene cuvettes. 
Preparation of NH2-PEO113-5-FAM-KCRGDC.  Three steps were involved to 
prepare NH2-PEO113-5-FAM-KCRGDC.  
BocNH-PEO113-NH2 (300 mg, 0.0600 mmol), was dissolved in 13 mL of 
dichloromethane and stirred at room temperature for c.a. 0.5 h.  Succinic anhydride 
(24.6 mg, 0.246 mmol) and DIPEA (21.0 μL, 15.5 mg, 0.120 mmol) were added.  The 
reaction mixture was allowed to stir at room temperature for 24 h.  The reaction mixture 
was then concentrated and precipitated into cold ether (40 mL) twice.  The precipitate 
was dried under vacuum to afford 238 mg of white solid as 
BocNH-PEO113-NHCOCH2CH2COOH (yield 80%).  1H NMR (CD2Cl2, 300 MHz, ppm): 
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δ 1.43 (s, C(CH3)3 on the Boc protecting group), 2.5-2.65 (br, -CH2CH2- of the succinic 
anhydride unit), 3.3-3.8 (br, -CH2CH2- of the PEG repeating unit), 5.0-5.1 (br, amide 
proton), 6.8-6.9 (br, amide proton). 
BocNH-PEO113-NHCOCH2CH2COOH (201 mg, 0.0402 mmol) was dissolved in 10 
mL of dichloromethane and stirred at room temperature for c.a. 0.5 h.  
N-hydroxysuccinimide (23.6 mg, 0.205 mmol) and N,N′-Dicyclohexylcarbodiimide (43.7 
mg, 0.211 mmol) were added.  The solution was allowed to stir at room temperature for 
24 h before being concentrated and precipitated into cold ether (40 mL) twice.  The 
precipitate was then dried under vacuum to afford a white solid, 
BocNH-PEO113-NHCOCH2CH2CO-NHS (151 mg, yield: 73%).  1H NMR (CD2Cl2, 300 
MHz, ppm): δ 1.43 (s, C(CH3)3 on the Boc protecting group), 2.5-2.65 (br, -CH2CH2- of 
the succinic anhydride unit), 2.8-2.9 (m, -CH2CH2- of the N-hydroxysuccinimide unit), 
3.3-3.8 (br, -CH2CH2- of the PEG repeating unit), 5.0-5.1 (br, amide proton), 6.8-6.9 (br, 
amide proton). 
5-FAM-KCRGDC (40.6 mg, 0.0390 mmol) was dissolved in 5 mL of anhydrous 
DMF, to this solution were also added BocNH-PEO113-NHCOCH2CH2CO-NHS (104 mg, 
0.0201 mmol) and DIPEA (10 μL, 7.3 mg, 0.057 mmol).  The reaction mixture was 
allowed to stir at room temperature for 24 h.  The reaction mixture was precipitated into 
cold ether (45 mL) once.  The solid was then dissolved in DCM and precipitated into 
cold ether (45 mL) twice to afford a yellow solid as 
BocNH-PEO113-NHCOCH2CH2CO-5-FAM-KCRGDC (100 mg, yield: 80%).  The 
peptide coupling efficiency was determined to be 60% by UV-vis. 
BocNH-PEO113-NHCOCH2CH2CO-5-FAM-KCRGDC (100 mg, 15.9 μmol) was 
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dissolved in 6 mL of DCM.  TFA (4.8 mL, 7.1 g, 62.3 mmol) was added.  The reaction 
mixture was allowed to stir at room temperature for 12 h, concentrated and precipitated 
into cold ether.  The precipitate was dried under vacuum to afford 
NH2-PEO113-5-FAM-KCRGDC as a yellow solid (80 mg, yield: 79%). 
General procedures for the preparation of 
NH2-PEO113-5-FAM-KCRGDC-g-mPEG2000-g-DOTAlysine-g-PAA-b-PS Block 
Copolymers.  The NH2-PEO113-5-FAM-KCRGDC was grafted onto 
mPEG2000-g-DOTAlysine-g-PAA-b-PS by following the procedures: to a solution of 
mPEG2000-g-DOTAlysine-g-PAA-b-PS in anhydrous DMF, 1-[3 ′
-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide (EDCI), and 
1-hydroxybenzotriazole (HOBt) were added, and the reaction mixture was allowed to stir 
for 1 h at room temperature.  Then DIPEA and a solution of 
NH2-PEO113-5-FAM-KCRGDC in anhydrous DMF were added and the reaction mixture 
was further stirred for 30 h at room temperature.  The relative ratio of 
mPEG2000-g-DOTAlysine-g-PAA-b-PS block copolymer/EDCI/HOBt/mPEG-NH2 was 
1:20:20:4.  Appropriate amount of DMF was added to the reaction mixture to adjust the 
polymer concentration to be 1.00 mg/mL.  Micelle was directly prepared from the 
reaction mixture and was crosslinked into SCKs.  The impurities were later removed by 
dialysis against nanopure water in MWCO 100 kDa dialysis tubings and/or by passing 
through a Sephadex® G75 SEM column. 
Preparation of HOOC-PEG30004.0-g-DOTAlysine3.2-g-PAA58.8-b-PS71 Block 
Copolymer.  Similar procedures were followed as mentioned above, except the 
attaching sequence. 
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PAA66-b-PS71 (50.6 mg, 0.0041 mmol) was dissolved in 8.0 mL of N2-flushed DMF.  
EDCI (37.3 mg, 0.125 mmol) and HOBt (17.2 mg, 0.127 mmol), both prepared as DMF 
solutions, were added into the polymer solution.  The reaction mixture was stirred at 
room temperature for 1 h.  DOTAlysine(tetra-t-butyl ester) (10.8 mg, 0.013 mmol) and 
DIPEA (100 μL, 0.57 mmol) were added to the reaction mixture as a DMF solution.  
The reaction mixture was allowed to stir at room temperature for 24 h, and was then 
transferred to MWCO 6-8000 Da dialysis tubing and dialyzed against nanopure water for 
4 d.  DOTAlysine(tetra-t-butyl ester)3.2-g-PAA62.8-b-PS71 was obtained after 
lyophilization as a white powder.  Yield, 36.2 mg, 60%.  The number of 
DOTAlysine(tetra-t-butyl ester) per polymer chain was determined by 1H NMR (coupling 
efficiency 90%).  1H NMR (DMSO-d6, 300 MHz, ppm): δ 1.10-2.20 (br, CH2 of the 
polymer backbone), 1.40 (s, C(CH3)3 of the t-butyl ester group), 2.20-2.64 (br, CH of the 
polymer backbone), 2.40-3.05 (br, DOTAlysine macrocyclic protons), 6.35-7.20 (m, 
5Ar-H). 
DOTAlysine(tetra-t-butyl ester)3.2-g-PAA62.8-b-PS71 (28.5 mg, 0.0022 mmol) was 
dissolved in 7.0 mL of N2-flushed DMF.  EDCI (32.8 mg, 0.110 mmol) and HOBt (14.8 
mg, 0.110 mmol), both prepared as DMF solutions, were added into the polymer solution.  
The reaction mixture was stirred at room temperature for 1 h.  NH2-PEG3000-COOH 
(21.9 mg, 0.0066 mmol) and DIPEA (100 μL, 0.57 mmol) were added to the reaction 
mixture as a DMF solution.  The reaction mixture was allowed to stir at room 
temperature for 24 h, and was then transferred to MWCO 50 kDa dialysis tubing and 
dialyzed against 5 mM PBS (pH ~ 7.4) for 4 d.  The polymer solution in 5 mM PBS was 
then passed through Sephadex® G50 SEC column with 150 mM PBS (pH ~7.4) as the 
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solvent.  The polymer fractions were combined and desalted through dialysis against 
nanopure water, followed by lyophilization to afford a white polymer as 
HOOC-PEG30004.0-g-DOTAlysine(tetra-t-butyl ester)3.2-g-PAA58.8-b-PS71.  Yield, 43.2 
mg, 82%.  The number of HOOC-PEG3000 per polymer chain was determined by 1H 
NMR (coupling efficiency, 80%).  Yield, 29.3 mg, 95%.  1H NMR (DMSO-d6, 300 
MHz, ppm): δ 1.10-2.20 (br, CH2 of the polymer backbone), 1.40 (s, C(CH3)3 of the 
t-butyl ester group), 2.20-2.65 (br, CH of the polymer backbone), 2.40-3.10 (br, 
DOTAlysine macrocyclic protons), 3.40-3.70 (br, mEEG backbone –OCH2CH2O- 
protons), (6.28-7.16 (m, 5Ar-H). 
HOOC-PEG30004.0-g-DOTAlysine(tetra-t-butyl ester)3.2-g-PAA58.8-b-PS71 (36.2 mg, 
0.0015 mmol) was dissolved in 2.0 mL of DCM.  TFA, 1 mL, was added to the polymer 
solution and the reaction mixture was allowed to stir at room temperature for 6 h.  The 
solvent and TFA were removed by blowing N2 to the surface of the reaction mixture and 
residual polymer was dissolved in DMF to afford an off-yellow solution.  The solution 
was dialyzed in MWCO 6-8000 Da tubing against nanopure water for 4 d.  A white was 
obtained after lyophilization of the solution in water as the 
HOOC-PEG30004.0-g-DOTAlysine3.2-g-PAA58.8-b-PS71.  Yield, 29.3 mg, 95%.  1H 
NMR (DMSO-d6, 300 MHz, ppm): δ 1.10-2.20 (br, CH2 of the polymer backbone), 
2.20-2.65 (br, CH of the polymer backbone), 2.40-3.10 (br, DOTAlysine macrocyclic 
protons), 3.40-3.70 (br, mEEG backbone –OCH2CH2O- protons), (6.28-7.16 (m, 5Ar-H). 
General procedures for micelle assembly and SCK formation.  To a solution of 
the amphiphilic block copolymer (PAA-b-PS, mPEG2000-g-DOTAlysine-g-PAA-b-PS, 
PEG113-5-FAM-KCRGDC-g-mPEG2000-g-DOTAlysine-g-PAA-b-PS, or 
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HOOC-PEG3000-g-DOTAlysine-g-PAA-b-PS) in THF or DMF, (ca. 1.0 mg/mL in 
polymer concentration), an equal volume of nanopure water was added dropwise via a 
syringe pump over 6 h.  The reaction mixture was further stirred for ca. 16 h at room 
temperature before transferring to a presoaked dialysis tubing (MWCO. 6,000-8,000 Da 
for PAA-b-PS; MWCO 100000 Da for 
PEG113-5-FAM-KCRGDC-g-mPEG2000-g-DOTAlysine-g-PAA-b-PS), and dialyzed 
against nanopure water for 4 days, to afford a micelle solution with the final polymer 
concentration of 0.20-0.30 mg/mL. 
General procedures for the PAA Block Crosslinking to Form SCKs.  To a 
solution of micelle in nanopure water, was added dropwise a solution of 
2,2’-(ethylenedioxy)bis(ethylamine) (c. a. 1.0 mg/mL) in nanopure water over 10 min.  
The reaction mixture was stirred for c. a. 2 h at room temperature.  To this solution, was 
added dropwise via syringe pump over 30 min, a solution of 
1-[3’-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide in nanopure water.  The 
reaction mixture was further stirred 20 h at room temperature before transferring to 
presoaked dialysis tubing, and dialyzed against nanopure water for 4 days, to remove all 
of the impurities and afford the SCK solution.  The nominal crosslinking extent (20% 
and 50%) were based on the stoichiometry of the crosslinker 
(2,2’-(ethylenedioxy)bis(ethylamine)) to that of the carboxylic acids on the PAA domain.  
The general stoichiometry employed to achieve 20% nominal crosslinking was 9:2.2:1 
for carboxylic acid units : EDCI : crosslinker, and to achieve 50% nominal crosslinking, 
the stoichiometry was 3.6:2.2:1. 
General procedures for post-attaching 
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KCRGDC/5-FAM-KCRGDC/PEG-5-FAM-KCRGDC onto micelle/SCK 
nanoparticles.  All micelle/SCK samples were pre-cooled to 4 °C.  Sulfo-NHS 
aqueous solution was then added, and the containers were shaken for c.a. 30 min.  
Freshly prepared EDCI aqueous solution was added and the reaction containers were 
shaken for 1.5 h in a 4 °C refrigerator.  Here, the pH values of the solutions were 
adjusted to around 7.4 with pH 9.2 0.2 M phosphate buffer.  
KCRGDC/5-FAM-KCRGDC/PEG-5-FAM-KCRGDC solutions were then added.  The 
pH of the reaction solutions were finally adjusted to around 7.4 (optimal pH for the 
coupling reaction to occur) and the reaction mixtures were kept shaking at 4 °C for 24 h.  
All reaction mixtures were then dialyzed against pH 7.4 5 mM PBS (after treatment of 
Chelax 100 resin to removed heavy metals) for 5 d.  The equivalence for the [COOH], 
[EDCI] and [sulfo-NHS] was controlled as 1:1.5:3.0, and the peptide amount was exactly 
based on stoichiometry. 
Reduction of disulfide bond on KCRGDC-NP to thiol for Ellman’s assay.  
Excess amount of DTT (DL-Dithiothreitol) was incubated with micelle/SCK 
nanoparticles labeled with the cyclic KCRGDC at 45 °C for 1h.  The reaction mixture 
was then dialyzed against nanopure water in pre-soaked MWCO 6-8000 Da dialysis 
tubing to remove unreacted DTT and for later quantification of thiol groups by Ellman’s 
assay. 
Protocol for Ellman’s assay 
26.0 mg of cysteine (Sigma) is dissolved into 10.00 mL of reaction buffer (0.10 M 
Sodium Phosphate Buffer pH 8.0) to make the stock solution.  4.00 mg of Ellman’s 
reagent (DTNB, Sigma) was dissolved into 1.00 mL of reaction buffer.  A series of 
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cysteine standard solutions with different concentrations are then prepared from the stock 
solution, with cysteine concentrations being 15.0 mM, 1.50 mM, 1.25 mM, 1.00 mM, 
1.00 mM, 0.75 mM, 0.50 mM, 0.25 mM and 0.05 mM.  The Ellman’s reagent solution 
was then mixed with the cysteine standard solutions and the samples to be measured 
using the following volumetric quantities 
Blank: 983 μL rxn. Buffer + 18 μL Ellman’s.   
Standards/Samples: 938 μL rxn buffer + 18 μL of Ellman’s + 45 μL sample. 
After 15 min from the mixing, absorbances were measured at 412 nm.  A standard 
curve can be generated and sample thiol concentrations can be determined. 
Procedures for running Sephadex® G75 gravity SEC columns to purify aqueous 
nanoparticle samples.  Sephadex® G75 resin (superfine) (10 g) was pre-soaked in 
boiling water for c.a. 30 min to form a gel.  After cooling to room temperature, the resin 
was packed into a glass column (30 cm × 2 cm) equipped with a stopcock.  About 200 
mL of the eluent (150 mM PBS, pH ~ 7.4) was passed through the column prior to any 
sample loading.  For each run, c.a. 4 mL of nanoparticle samples (with polymer 
concentration around 0.20-0.30 mg/mL) was loaded.  The separation process was 
monitored by UV.  Columns were reused after being flushed with plenty of the eluent.  
The desired fractions were collected and concentrated and solvent-exchanged into 5 mM 
PBS by using Centricon (MWCO 10000 Da, Millpore, MA) tubes. 
Preparation of FITC-functionalized micelles  
mPEG20002.4-g-DOTAlysine2.0-g-PAA59.6-b-PS54 (15.9 mg, 0.99 μmol) was dissolved in 
7.0 mL of anhydrous DMF and the solution was stirred for 1 h at room temperature.  
EDCI (1.23 mg, 4.1 μmol) and HOBt (0.56 mg, 4.2 μmol) were added as DMF solutions 
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into the polymer solution.  The reaction mixture was allowed to stir at room temperature 
for 1 h.  Fluorescein-5-thiosemicarbazide (1.0 mg, 2.36 μmol) was added as a DMF 
solution.  The reaction mixture was further stirred at room temperature for 24 h.  
Proper amount of DMF was added to the reaction mixture to make the polymer 
concentration to be c.a. 1 mg/mL.  Micelle was then directly prepared from the reaction 
mixture by dropwise addition of water over 6 h.  The DMF/water mixture was 
transferred to MWCO 6-8000 Da tubing and dialysed against 5 mM PBS (pH ~7.4) to 
afford the final micelle solution in water with polymer concentration to be 0.262 mg/mL.  
The FITC attached to the polymer was quantified by measuring its UV absorbance at 492 
nm and using a molar extinction coefficient of 63000 M-1cm-1.  The average number of 
FITC per polymer chain was determined to be 0.2. 
Procedures for integrin binding assay (Performed by Ms. Ashley L. Fiamengo in 
Prof. Carolyn J. Anderson’s laboratory at Washington University School of 
Medicine):  An isolated, competitive binding assay described previously33, 37 is utilized 
here.  Briefly, vitronectin (Chemicon CC080) was biotinylated with 
N-hydroxysuccinimide biotin (2 h at room temperature) before dialysis into PBS, pH 7.4. 
The wells of a 96-well plate (Nunc Immuno Plate with MaxiSorp) were coated with 100 
µg integrin αvβ3 or αvβ5 (Chemicon CC1019 and CC1025, respectively) in coating buffer 
(20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 10 µM MnCl2).  The 
plates were then blocked (1 h at 4 °C) with bovine serum albumin (BSA) (3% in coating 
buffer).  After washing three times with binding buffer (0.1% BSA in coating buffer), 
biotinylated vitronectin (final concentration 14 nM) with and without serially diluted 
ligands was allowed to bind to the integrins (3 h at 37 °C). After washing (3 times in 
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binding buffer), bound biotinylated vitronectin was detected by binding ExtrAvidin 
alkaline phosphatase (Sigma) (1/35,000 dilution, 1 h at room temperature) using the 
p-nitrophenyl phosphate liquid substrate system (Sigma) as the chromogen.  Each 
concentration data point was done in triplicate, and each binding experiment was 
performed at least twice.  Nonlinear regression was used to fit binding curves and 
calculate inhibitory concentrations of 50% (IC50 values) (Prism, version 5.02; GraphPad). 
Procedures for cell assay of 5-FAM-KCRGDC-labeled nanoparticles 
(Performed by Dr. Zhiqiang Xu in Prof. Jeffery R. Leonard’s laboratory at 
Washington University School of Medicine):  5000 human U87MG glioma cells were 
seeded on glass coverslip in a 24-well plate at 37 °C for 12 h before the experiment.  
5-FAM-KCRGDC-labeled nanoparticles were then added directly into the media 
(alpha-MEM(Gibco)) at concentration of 1 μM based on the conjugated 
5-FAM-KCRGDC peptide.  After 24 h treatment all the wells were fixed with 4% 
paraformaldehyde and cell nucleus was counterstained with DAPI.  Fluorescence signal 
was recorded using epifluorescence microscope.  All the pictures were taken at same 
time constant without any post modification. 
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Results and Discussion 
To create a functional nanomaterial that is capable of carrying imaging and/or 
therapeutic agents to a selective tissue site, it is imperative that the targeting ligand be 
accessible for binding with the receptor target.  Two general approaches, the 
post-conjugation method and the pre-conjugation method, were, therefore, applied to 
afford micelle/SCK nanoparticles functionalized with a disulfide-cyclized RGD peptide, 
KCRGDC.  For the post-conjugation method, SCK nanoparticles were first prepared 
from the amphiphilic diblock copolymer precursors (PAA-b-PS), according to our 
established protocol, the cyclic KCRGDC peptide or the amine-terminated 
PEO113-5-FAM-KCRGDC were then conjugated onto the nanoparticle shell domain 
through carbodiimide-mediated aqueous amidation  (see Experimental Section for 
details).  For the pre-conjugation method, the PAA-b-PS block copolymers were 
modified with the KCRGDC peptides via amidation chemistry in organic solvent, 
followed by aqueous assembly into nanostructures and crosslinking across the shell 
domain of nanoparticles.27, 28  Coincident with these synthetic efforts were rigorous 
physicochemical studies to determine the composition and structure of the resulting 
materials, and biological evaluations to determine the binding affinities between the 
ligand bound to the nanostructure and receptors either coated on a plate or presented on 
cells.  The synthetic work and physicochemical studies were the focus of my work, 
whereas the biological studies were performed by experts through collaborations. 
 
Post-conjugation of KCRGDC peptide onto micelles and SCKs. 
 As depicted in Scheme 2-1, the KCRGDC peptide was attached onto pre-established  
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micelles and SCKs from PAA61-b-PS34 block copolymer precursor.  The synthetic 
process was based upon modified carbodiimide-mediated aqueous amidation.  The 
first step, activation of carboxylic acid residue, involved the pH value adjustments of 
reaction media (see Experimental Section for details)29, 30 to avoid unexpected side 
reactions, such as the hydrolysis and rearrangement of the activated intermediates.  
The KCRGDC solution was then added to the reaction mixtures and the final pH 
values of the reaction mixtures were again adjusted to ~ 7.5, which was reported to be 
the optimum pH value for aqueous amidation reactions facilitated by sulfo-NHS.31  
Different amounts of peptide (nominal 4, 40, and 400 peptides per micelle/SCK, 
respectively) were conjugated to the nanoparticles by controlling the coupling 
stoichiometry between the acrylic acid residues per nanoparticle and the KCRGDC 
peptide, and the equivalence of EDCI, sulfo-NHS and KCRGDC was controlled to be 
1:2:1. 
 Quantification of the KCRGDC peptides attached onto the micelle/SCK 
nanoparticles were determined by the Ellman’s assay, a conventional technique used 
for the quantification of thiol (-SH) groups in biological studies.32  To convert the 
disulfide bond in the cyclic KCRGDC peptide to thiols, dithiothreitol (DTT) was used 
(Scheme 2-2) as the reducing agent.  The KCRGDC-functionalized nanoparticles 
with the disulfide bond reduced to thiols were then analyzed for thiol quantity by 
Ellman’s assay as described in the experimental section. 
Table 2-1 summarizes the actual average numbers of KCRGDC peptides attached 
on each nanoparticle, determined by Ellman’s assay.  The best peptide coupling 
efficiency was found to be ~ 15% and the lowest coupling efficiency was ~ 3%.  As 
a note, for the two samples with nominal 4 peptides per nanoparticle, quantification of 
the peptide by Ellman’s assay could not provide reliable results due to the very low 
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concentration of the formed thiol groups.  The low coupling efficiency could be 
attributed to the steric hindrance between the cyclic KCRGDC peptide and the 
activated ester throughout the shell domain of the nanostructures.  As we have 
already noticed in previous study,28 the spacer length between the reacting amine 
group and the cyclic moiety greatly affected the coupling efficiency.  Meanwhile, the 
electronic property of the peptide hydrate might also influence the reaction efficiency. 
 
 
Table 2-1.  IC50 values of KCRGDC-micelle/SCKs prepared by post-conjugation method. 
IC50 (nM)d Samples Naggr. 
Peptide 
per NPa 
Peptide 
per NPb αvβ3 αvβ5 
KCRGDC    10.5 921 
Micelle 125 0 0 > 10,000 > 10,000 
20% Crosslinked SCK 125 0 0 > 10,000 > 10,000 
50% Crosslinked SCK 125 0 0 > 10,000 > 10,000 
125 4 n.a.c > 10,000 1.5 
125 40 < 1 > 1,000 0.3 KCRGDC-Micelle 
125 400 65 1,080 26.1 
125 4 n.a. > 5,000 > 10,000 
125 40 < 1 > 1,000 > 10,000 KCRGDC-SCKs 20% Crosslinked 125 400 58 > 1,000 > 5,000 
125 4 n.a. > 1,000 > 10,000 
125 40 < 1 380 > 5,000 KCRGDC-SCKs 50% Crosslinked 125 400 42 37.4 > 10,000 
a nominal numbers of peptide per nanoparticle (NP) from stoichiometry; b numbers of 
peptide per nanoparticle measured from Ellman’s assay; c not available, due to the very low 
UV signals obtained; d IC50 values for micelle/SCKs were measured to be the concentrations 
of the nanoparticles in units of nM. 
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The in vitro αvβ3 binding affinity (IC50 value) of the peptide-functionalized 
nanoparticles was then conducted by following the plate-assay protocol for peptides.33  
The binging specificity was determined by comparing the affinity (IC50 values) 
between αvβ3 and αvβ5.  The results of these assays were also outlined in Table 2-1. 
For all of the surveyed post-KCRGDC-modified micelles and 20% crosslinked 
SCKs, poor binding affinities to αvβ3 (IC50 > 1 μM, i.e. over 100-folds of decrease, 
relative to the control peptide) were observed.  Compared to micelles and 20% 
crosslinked SCKs, enhanced binding affinity, together with the selectivity, to αvβ3 
were achieved for the 50% crosslinked SCKs.  Meanwhile, as the number of 
peptides per SCK increased from less than 1 to ca. 52, the IC50 value towards αvβ3 
decreased from 380 nM to 37.8 nM, i.e., a 10-fold of improvement.  It was 
hypothesized that, for the SCKs with the higher crosslinking extents, the chances for 
the peptide to react with activated carboxylates beneath the shell domain would 
decrease due to the framework-like property of the shell domain.  Therefore, most of 
the peptides attached to the nanoparticle were located on the outer surface or 
periphery of the SCKs and were more accessible for the integrin binding.  An 
interesting phenomenon was observed that the KCRGDC-micelle samples showed 
very good binding to αvβ5, although the peptide itself has poor binding to αvβ5.  The 
reason behind this observation was not clear at this stage. 
Post-conjugation of NH2-PEO113-5-FAM-KCRGDC onto PEGylated SCKs 
prepared from mPEG20005.5-g-DOTAlysine2.0-g-PAA58.5-b-PS54. 
As mentioned in the previous section, the targeting peptide binding affinity could 
be enhanced by the means of accommodating the peptides away from the nanoparticle 
moieties.  To further explore the “lengthening” effect and provide more accurate 
quantification of conjugated peptides per nanoparticle without using the tedious 
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Ellman’s assay, NH2-PEO113-5-FAM-KCRGDC, a KCRGDC derivative was 
synthesized according to Scheme 2-3 and coupled to PEGylated SCKs as depicted in 
Figure 2-1 (also see Experimental Section for details).  The 5-FAM was introduced 
as a chromophore for more convenient UV-vis quantification of the peptides 
covalently attached onto nanoparticles. 
With the ultimate goal for developing targeting nanoparticles as potential in vivo 
imaging contrast agents, we used the PEGylated SCK nanoparticles, which have 
already been demonstrated with sufficient blood circulation time (half-life up to 16 h), 
to evaluate the targeting efficiency after decorating with the peptide ligands.  
PEGylated SCKs with 20% and 50% crosslinking extents were prepared from 
mPEG20005.5-g-DOTAlysine2.0-g-PAA58.5-b-PS54 block copolymer precursors.27  
The DOTA molecules acted as the chelator for radionuclide 64Cu, a promising PET 
imaging tracer. 
The synthetic sequence of NH2-PEO113-5-FAM-KCRGDC initialized with the 
installation of carboxylic acid group to the mono-Boc protected diamino-PEO113 
(compound 1), followed by functional group transformation to the activated ester 
(compound 3).  Compound 3 was then reacted with 5-FAM-KCRGDC (structure 
shown in Scheme 2-3) via amidation chemistry to attach the peptide onto the PEG 
chain end (compound 4).  The Boc protecting group was then removed to afford 
NH2-PEO113-5-FAM-KCRGDC as the final product (compound 5).  The molar 
extinction coefficient of the 5-FAM-KCRGDC in 5 mM PBS (pH ~ 7.4 with 5 mM of 
NaCl) at 492 nm was determined to be 63,000 M-1cm-1 and was also used as the molar 
extinction coefficient for the NH2-PEO113-5-FAM-KCRGDC.  The coupling 
efficiency of the peptide to the PEG chain was thus determined to be 60%, based 
upon UV-vis measurement. 
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For the conjugation of NH2-PEO113-5-FAM-KCRGDC onto the PEGylated 
nanoparticles, similar procedures to the one mentioned above were followed (Figure 
2-1, see Experimental Section for details).  After extensive dialysis against 5 mM 
PBS (pH ~ 7.4 with 5 mM of NaCl) to remove small molecule byproducts and the 
unattached NH2-PEO113-5-FAM-KCRGDC, the amounts of the KCRGDC attached 
onto the nanoparticles were then determined by measuring the UV-vis absorption of 
these nanoparticles at 492 nm. 
The coupling efficiency was found to be extremely low as shown in Table 2-2 
(0.6% and 0.4% for 20% and 50% crosslinked PEGylated SCKs, respectively).  The 
fact that the SCKs were surrounded by a layer of hydrated PEO could be attributed as 
the source for the low coupling efficiencies.  The PEO layer not only hindered the 
big molecule, NH2-PEO113-5-FAM-KCRGDC, to get access to the activated 
carboxylic acid groups in the shell of the nanoparticles, but also affected the 
activation step due to the reduced permeability of the SCK shell domain.  
Comparing to KCRGDC, whose IC50 value to αvβ3.was 10.5 nM, both 
5-FAM-KCRGDC and PEO113-5-FAM-KCRGDC showed slightly decreased binding 
affinities to αvβ3, which was 23.0 and 21.3 nM, respectively.  Due to the inadequate 
number of peptides per SCK nanoparticle (ca. 6 and 4 for 20% and 50% crosslinked 
PEGylated SCKs, respectively, Table 2-2), no appreciable binding to αvβ3 was 
observed for both the KCRGDC functionalized 20% and 50% crosslinked PEGylated 
SCKs (IC50 up to 10,000 nM, Table 2-2).  In fact, the previous results obtained from 
the “native” SCK experiments (vide supra) have already indicated that a minimum 
amount of 40 KCRGDCs per nanostructure was required to achieve comparable 
binding affinity. 
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Table 2-2.  IC50 values of PEGylated SCKs, post-conjugated with 
NH2-PEO113-5-FAM-KCRGDC. 
IC50 (nM)c Samples Naggr. Peptideper NPa
Peptide
per NPb αvβ3 αvβ5 
5-FAM-KCRGDC    23.0 > 1,000 
PEO113-5-FAM-KCRGDC    21.3 > 1,000 
20% Crosslinked 
PEO113-5-FAM-KCRGDC-SCK
200 1000 6.3 > 1,000 > 10,000
50% Crosslinked 
PEO113-FAM-KCRGDC-SCK
200 1000 4.2 > 5,000 > 10,000
a targeted number of peptide per nanoparticle based on stoichiometry; b number of peptide 
per nanoparticle as determined by UV-vis (ε492nm = 63,000 M-1cm-1); c IC50 values for 
micelle/SCKs were measured to be the concentrations of the nanoparticles in units of nM. 
 
The observed trend, i.e., the improvement of αvβ3 binding affinity for the 
KCRGDC-functionalized nanostructure with the increased amount of peptide per 
nanoparticle, clearly indicated the direction for advancing αvβ3 targeting.  However, 
the post-conjugation methodology limited the progress due to the following two 
concerns: 1) the low reaction efficiency caused unnecessary waste of the peptides and 
increased the purification difficulty since over 80% of the reacting peptides were 
keeping “free” inside the reaction mixture; and 2) the problem associated with the 
quantification of conjugated peptides.  These dilemmas made the post-modification 
approach less attractive and therefore, the alternative and facile pre-conjugation 
strategy was applied for the next studies (vide infra). 
Construction of targeting SCKs through pre-conjugation methodology. 
During our earlier works for construction of DOTA-SCKs with remarkable 
radiolabeling efficiency and PEGylated SCKs with tunable biodistributions,27 a 
pre-grafting strategy has been developed and demonstrated as a facile and practical 
approach for attaching large amount of functionalities to nano-materials.  This 
strategy was extended to this study including the following modified protocols: Firstly, 
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the NH2-PEO113-5-FAM-KCRGDC molecules were conjugated onto the 
mPEG2000-g-DOTAlysine-g-PAA-b-PS block copolymer precursors with different 
length ratios of PAA vs. PS in organic solvents (DMF in this study) through 
carbodiimide-mediated amidation chemistry facilitated by HOBt (Scheme 2-4); 
Secondly, the concentrations of block copolymer precursors in reaction mixtures were 
adjusted to ca. 1 mg/mL by adding appropriate amounts of DMF.  Equal volume of 
nanopure water (> 18.0 MΩ cm) to that of the DMF was then directly added to the 
reaction mixture over 6 h to induce the micellization process and “frozen” the formed 
micelle structures; Finally, SCKs were prepared by crosslinking of the carboxylic acid 
groups throughout the micelle shell domain with 2,2′-(ethylenedioxy)-bis(ethylamine) 
via amidation chemistry.  Initially, the micelles and SCKs were purified through 
extensive dialysis as described before.  However, the fast protein liquid 
chromatography (FPLC) analyses of these samples indicated the existence of 
unconjugated NH2-PEO113-5-FAM-KCRGDC as shown in Figure 2-2.  Therefore, 
the nanoparticles were further purified through Sephadex® size exclusion column 
chromatography (SEC) for the total removal of free peptides. 
Different Sephadex® resins were surveyed, including G25 medium (bead size 
50-150 μm, fractionation range 100-5000 Da), G50 medium (bead size 50-150 μm, 
fractionation range 500-10000 Da), G75 medium (bead size 50-150 μm, fractionation 
range 1000-50000 Da), and G75 superfine (bead size 20-50 μm, fractionation range 
1000-50000 Da).  Although the molecular weight of NH2-PEO113-5-FAM-KCRGDC 
was ~ 6,300 Da, its complete removal was only achieved by columns packed with 
superfine G75 resins.  The columns were monitored with UV-vis by measuring the 
absorbance of each collected fraction (ca. 4  
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mL) at 492 nm.  Figure 2-3 showed that three distributions were separated by the 
column, with the first one (left) as the nanoparticle fraction, the second one (middle) 
as the NH2-PEO113-5-FAM-KCRGDC, and the third one (right) possibly as the 
5-FAM-KCRGDC precursor (contamination during the synthetic process of 
NH2-PEO113-5-FAM-KCRGDC).  The purity of the nanoparticle fraction was further 
confirmed by FPLC (Figure 2-3).  The nanoparticle fractions were then combined 
and concentrated by Centricon (MWCO 10000 Da) to make the final polymer 
concentrations around 0.25 mg/mL.  After quantification of the peptide amount 
attached, these samples (samples 2-5 in Table 2-3) were then measured for IC50 values 
to αvβ3. 
As characterized by transmission electron microscopy (TEM), these nanoscale 
objects exhibited globular shape (Figure 2-4) and relatively narrow size distributions.  
Detailed characterization data and the IC50 values are summarized in Table 2-3.  
Compared to the post-conjugation method, the pre-conjugation method provided 
increased amount of peptide incorporated into the nanoparticles, as a result of the 
improved coupling efficiency for amidation reactions conducted in DMF rather than 
water (Table 2-3). 
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Figure 2-3.  Monitoring Sephadex® G75 superfine column 
fractions by measuring UV absorbance at 492 nm. 
 
 
 
 
A B D C
Figure 2-4. Transmission electron microscopy (TEM) images of PEGylated 
micelle/SCK nanoparticles, prepared from pre-labeling the 
NH2-PEG5000-5-FAM-KCRGDC onto the amphiphilic PAA-b-PS block copolymers.  
A, micelle from 
mPEG20002.4-g-DOTAlysiney2.0-g-PEO113-5-FAM-KCRGDC0.6-g-PAA59-b-PS54; B, 
50% crosslinked SCK from 
mPEG20002.4-g-DOTAlysiney2.0-g-PEO113-5-FAM-KCRGDC0.6-g-PAA59-b-PS54; C, 
micelle from DOTAlysiney2.5-g-PEO113-5-FAM-KCRGDC0.5-g-PAA65-b-PS70; D, 
50% crosslinked SCK from 
DOTAlysiney2.5-g-PEO113-5-FAM-KCRGDC0.5-g-PAA65-b-PS70.  Scale bar 100 nm. 
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Samples 2-5 in Table 2-3 were prepared through the pre-conjugation method 
from NH2-PEO113-5-FAM-KCRGDC functionalized PAA66-b-PS71 and 
mPEG20005.5-g-DOTAlysine2.0-g-PAA58.5-b-PS54 block copolymer precursors.  
Despite of the fact that the nanoparticles were functionalized with more than 100 
peptides per particle on average, the binding affinities for αvβ3 remained lower, 
compared with the NH2-PEO113-5-FAM-KCRGDC control (Table 2-3).  No 
appreciable binding were observed even for nanoparticles with concentration up to 
100 nM, which meant that more than five ligand-modified nanoparticles (with totally 
more than 500 peptides attached) were required to provide similar binding capacity as 
one NH2-PEO113-5-FAM-KCRGDC small molecule.  The lower binding affinity of 
these nanoparticles suggested that the majority of the attached peptides might be 
located underneath the particle surface and were not available for binding to integrin 
receptors. 
Post-conjugation of KCRGDC to PEGylated micelles and SCKs bearing 
periphery carboxylic acids to achieve better accessibility of the peptides for 
integrin binding. 
Based upon all of the above results, a new method was then developed, to afford 
nanoparticles with KCRGDC peptide attached to the outer surface (Scheme 2-4).  In 
this method, the PEGylated nanoparticles were still constructed from micellization of 
PEO-g-PAA-b-PS amphiphilic block copolymers, however, the PEO grafts carried 
carboxylic acid chain termini instead of unreactive methoxy groups as in the previous 
studies.  The core-shell morphology of the micelles enabled some of the acid chain 
ends to be located on the periphery of the micelles (vide infra).  The peptide, 
5-FAM-KCRGDC was then conjugated to the micelles by methods described above 
in aqueous conditions.  Crosslinking the shell domain with di-amino crosslinkers 
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afforded the corresponding SCKs. 
 From the amphiphilic block copolymer, PAA66-b-PS71,34 DOTAlysine(tetra 
t-butyl ester) and NH2-PEG3000-OC3H6-COOH were attached sequentially through 
amidation chemistry, as described above, to afford the product, 
HOOC-PEG30004-g-DOTAlysine(tetra t-butyl ester)3-g-PAA59-b-PS71.  The average 
numbers of DOTA and PEG3000 on each polymer chain were determined by 1H 
NMR spectroscopy.  Protected forms of the DOTA derivatives were used to avoid 
the consumption of carboxylic acid residues on the DOTA moiety during the 
amidation process, which has already been demonstrated to be critical for retaining 
efficient 64Cu chelation.35  The existence of t-butyl esters also facilitated the 1H 
NMR quantification of the number of DOTAs per polymer chain, due to their unique 
characteristic resonance signals.  The copolymers were then subjected to acidolysis 
by trifluoroacetic acid to remove the t-butyl ester protecting groups to afford 
HOOC-PEG30004-g-DOTAlysine3-g-PAA59-b-PS71.  Micelles were then assembled 
through the conventional phase-segregation driven protocol and purified through 
regular dialysis against nanopure water to remove the organic solvent.  The aqueous 
micelle solution was then subjected to shell crosslinking reaction with 
2,2’-(ethylenedioxy)bis(ethylamine) to afford the SCKs with nominal 50% 
crosslinking extent.  Both the micelle and the SCKs were purified by running 
Sephadex® G75 superfine columns to remove unattached PEG chains. 
These PEGylated nanostructures were characterized through the combination of 
dynamic light scattering (DLS) and TEM.  Given the number-averaged 
hydrodynamic diameter of 32 nm (measured by DLS, see Experimental Section for 
details) and the averaged diameter of 26 nm for the PS core domain (obtained from 
TEM image analysis), the averaged shell thickness was ~ 3 nm.  For the PEG3000 
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molecule, the radius of gyration was calculated to be ca. 2.3 nm,36 therefore, it was 
reasonable to speculate that a considerable amount of the COOH-terminated PEO 
chain ends would be exposed around the periphery of PEGylated nanospheres.  After 
installation of 5-FAM-KCRGDC functionalities according to the established aqueous 
amidation methodology and purification through Sephadex ® G75 superfine columns 
column chromatography, the purity of these samples was confirmed by FPLC 
(performed by Dr. Yongjian Liu).  The final polymer concentrations of both targeting 
micelle and 50% crosslinked SCKs were adjusted to around 0.20 mg/mL through 
Centricon (MWCO 10000 Da) and their IC50 values to αvβ3 were measured (Table 
2-4).  Greatly enhanced bindings to αvβ3 were found both the micelle and SCKs, 
whose IC50 values were determined to be 1.38 nM and 0.49 nM, respectively.  The 
excellent IC50 values for these nanostructures indicated that by this synthetic approach, 
peptides attached on the nanoparticles were most likely on the outer surface of the 
nanoparticles and thus allowed efficient binding with integrins. 
 
Table 2-4.  Characterization data and IC50 values of 5-FAM-KCRGDC-labeled 
nanoparticles by Post-labeling KCRGDC onto micelles with PEG-COOH on the 
surface. 
DTEM IC50 (nM)a samples description 
nm 
Naggr.
Peptide 
per NP2 αvβ3 
6 Micelle-5-FAM-KCRGD 26 ± 3 825 170 1.38 
7 SCK-5-FAM-KCRGD (50% crosslnked) 26 ± 3 825 170 0.49 
a IC50 values for micelle/SCKs were measured to be the concentrations of the 
nanoparticles in units of nM. 
 
Internalization of KCRGDC-conjugated nanoparticles in U87MG glioma cells 
(performed by Dr. Zhiqiang Xu). 
Besides measuring the IC50 values in a plate assay, in vitro cell internalization 
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studies with U87MG glioma cell line for these nanoparticles were also performed.  
All six KCRGDC peptide conjugated samples (samples 2-7) showed binding to the 
glioma cells (Figure 2-5).  Cold competition (10 μM unlabeled KCRGDC combined 
with 1 μM of sample 7 (in peptide concentration)) was found to significantly attenuate 
both the binding and internalization of sample 7 to the glioma cells (from comparison 
of Figure 2-5 with Figure 2-6).   
As a control, a Fluorescein-5-thiosemicarbazide (FITC) conjugated polymer, 
mPEG20002.4-g-DOTAlysine2.0-g-FITC0.2-g-PAA59.4-b-PS54, was prepared from FITC 
and mPEG20002.4-g-DOTAlysine2.0-g-PAA59.6-b-PS54, via amidation chemistry 
described above.  Micelle prepared from this polymer showed no appreciable binding 
to U87MG glioma cells (Figure 2-7), indicating that the binding of 
KCRGDC-conjugated nanoparticles to the cells was a result from the conjugated 
KCRGC peptide. 
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Sample 9 
Sample 10 
Sample 13 
Sample 14 
Sample 11 
Sample 12 
       DAPI        5-FAM-RGD       merge 
Figure 2-5.  Human U87MG glioma cells treated with 1 μM RGD-labeled NPs for 
24 h at 37 °C. Scale bar: 50 μm. 
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   DAPI                       5-FAM-RGD                   merge 
Figure 2-6.  Cold competition study conducted by treating U87MG cells with 1 μM 
RGD-labeled NP (sample 14) and a ten fold excess of KCRGDC (10 μM) for 24 h.  
   DAPI                       5-FAM-RGD                   merge 
Figure 2-7.  Control study conducted by treating U87MG cells with 1 μM 
unconjugated, FITC-labeled micelle for 24 h. 
 
 
Conclusions 
Methods to develop shell crosslinked nanoparticles bearing cyclic KCRGDC 
peptide as the nanoscale antagonist to αvβ3 integrin were described in this study.  
The best synthetic approach for attaching large amounts of peptides onto 
nanoparticles has been established by “hybridizing” the pre-grafting and 
post-modification strategies, i.e., construction of nano-scale platforms bearing large 
and tunable quantities of periphery functionalities through the “pre-graft” 
methodology and then post-modification of these “outer” functionalities with the 
biologically-active targeting peptides.  Optimization of this synthetic methodology 
and the resulting nanomaterials required a multidisciplinary collaborative approach.  
The advantages of this synthetic pathway were highlighted by the ~ 10-fold improved 
binding affinity, obtained from the in vitro plate-based assays.  The RGD-labeled 
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nanoparticles showed strong specific binding to U87MG glioma cells.  With the 
good targeting capabilities, sufficient blood retention of these PEGylated SCKs,27 as 
well as with efficient radionuclide labeling for PET imaging,35 these nanoparticles 
possess good potential to be developed into nanoscale diagnostic and therapeutic 
agent delivery vehicles. 
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Chapter 3 
 
Nanostructures from Amphiphilic Hyperbranched Fluoropolymers 
(HBFP) for Imaging and Therapeutic Delivery in the Diagnosis and 
Treatment of Pediatric Brain Cancers 
 
 
Abstract 
In this chapter, nanoscale micelles from a novel amphiphilic hyperbranched 
fluoropolymer were studied as drug delivery agent assemblies.  The polymer was 
constructed by a published procedure that involved atom transfer radical polymerization 
(ATRP) from consecutive copolymerizations of 4-chloromethylstyrene with dodecyl 
acrylate and then 1,1,1-trifluoroethyl methacrylate with tert-butyl acrylate, followed by 
acidolysis to afford the hydrophilic acrylic acid residues.  Cascade blue was 
functionalized onto these micelle structures as a fluorescence reporter.  F3, a 31 amino 
acid sequence (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) which binds 
specifically to nucleolin was conjugated onto the micelles as the targeting agent.  
Doxorubicin (Dox), a drug widely used in chemotherapy treatments for many types of 
cancer, was used as the therapeutic agent.  The Dox-loaded and F3-conjugated 
nanoparticles were tested for in vivo effects using a murine intracranial U87MG glioma 
xenograft tumor model.  Specific binding to the tumor-associated angiogenic endothelial 
cells was observed for F3-peptide conjugated nanoparticles.  Compared to untargeted 
nanoparticles (scramble-peptide conjugated nanoparticles) F3-peptide conjugated 
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targeting nanoparticles (NP) were concentrated more in the angiogenic tumor blood 
vessels.  Also, Dox carried by these nanoparticles can cause apoptotic effects on the 
targeted tumor cells, which is expected to lead to targeted therapeutic benefits.   
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Introduction 
The central nervous system (CNS) is the most common site of primary solid tumors 
in children.1-4  Glioblastoma multiforme (GBM) is a highly malignant tumor in CNS.5, 6  
Patients diagnosed with GBM usually live less than one year after surgery despite 
intensive chemotherapy and radiation.7  One of the biggest challenges for treating these 
patients is lack of effective therapeutics that could efficiently pass blood brain barrier 
(BBB) and specifically target to the tumor site.8-11  Recent studies using nanoparticles as 
the carrier to deliver both diagnostics and therapeutics have shown promising results 
among non-CNS malignant tumors.12-15  However, there have been very few studies using 
nanoparticles as therapeutic delivery vehicle for the treatment of GBM.  Compared to 
traditional drug carriers, nanoparticle has several advantages such as their extremely 
small sizes (5-10 nm); possibility of conjugating multifunctional groups onto their 
surface; and increased retention time and better bio-distribution with PEG-modified 
nanoparticle.16-19 
Nucleolin is a phosphoprotein that normally resides in the nucleolus and also plays 
very important roles in rDNA transcription, ribosome assembly and ribosome 
biogenesis.20-24  Certain cancers such as breast cancer show significant up regulation and 
surface expression of nucleolin protein.25  As a binding partner for Nucleolin, HMN2 
(high mobility protein group 2) has been shown strong interaction with nucleolin in the 
nucleus.26  A small peptide (F3 peptide), previously characterized based on sequence 
homology to HMN2 demonstrated significant binding and internalization both into cancer 
cell and angiogenic blood vessels.27-29  Previously we have shown that doxorubicin-
loaded nanoparticles from hyperbranched fluoropolymers demonstrated significant 
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cytotoxic effects on U87MG glioma cell line in vitro.30  To further explore possibility of 
utilizing this system in vivo and specifically targeting glioma tumor cells, in the present 
study we designed a strategy of conjugating F3 peptide to our nanoparticle and tested in 
vivo effects of this targeting nanoparticle loaded with doxorubicin using U87MG glioma 
xenograft tumor model.  Our preliminary results showed that F3-peptide conjugated 
targeting nanoparticle not only specifically bound to the tumor-associated angiogenic 
endothelial cells, doxorubicin carried by these nanoparticles also caused apoptotic effects 
on the targeted tumor cells.  Compared to untargeted nanoparticles (scramble-peptide 
conjugated nanoparticles), F3-conjugated targeting nanoparticle were concentrated more 
in the angiogenic tumor blood vessels.  Improved biodistribution was achieved by 
functionalization these nanoparticles with a 750 Da poly(ethylene glycol).  This system 
will not only provide a novel approach to efficiently deliver therapeutics to the targeted 
tumor site it also potentially attenuate systemic side effects by free Doxorubicin. 
 
Experimental 
Materials.  All chemicals were purchased from Sigma-Aldrich Chemical Company, 
unless otherwise noted.  Poly(ethylene oxide) amine (PEO15-NH2, Mn = 750 Da) was 
purchased from Interzyne (Tampa, FL) and used without further purification.  Nanopure 
water (18 MΩ⋅cm) was acquired by means of a Milli-Q water filtration system (Millipore 
Corp.; Bedford, MA).  The peptides: F3, FITC-F3, and scrambled F3 
(KDEARALPSQRSRKPAPPKPEPKPKKAPAKK), were customized from Chengdu 
Kaijie Biopharmaceuticals Co. Ltd., Chengdu, China, and was used as received.  Supor 
25 mm 0.1 μm Spectra/Por Membrane tubes (molecular weight cutoff (MWCO) 6-8000 
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Da), purchased from Spectrum Medical Industries Inc., were used for dialysis.  Superfine 
Sephadex ® G75 resin (bead diameter: 20-50 μm; fractionation range: 1000-50000 Da 
(Dextrans)) was purchased from GE Healthcare and was used to purify aqueous 
nanoparticle samples.  Centricon tubes (Amicon Ultra 4, 30 kDa MWCO) were 
purchased from Millipore Corp., MA. 
The hyperbranched amphiphilic fluoropolymer was synthesized by Dr. Wenjun Du 
as previously reported (polymer 4b).31 
5 mM PBS (phosphate buffered saline, with 5 mM of phosphates and 5 mM of NaCl) 
was prepared by mixing NaH2PO4 (0.76 g), Na2HPO4 (1.93 g) and NaCl (1.17 g) into 4 
liters of nanopure water and has a pH ~7.4.  150 mM PBS (phosphate buffered saline, 
with 150 mM of phosphates and 150 mM of NaCl) was prepared by mixing NaH2PO4 
(22.7 g), Na2HPO4 (59.0 g) and NaCl (35.1 g) into 4 liters of nanopure water and was 
used as the solvent for running Sephadex® columns (pH ~7.4). 
Instrumental.  1H NMR spectra were recorded at 300 on a Varian Unity-plus 300 
spectrometer, with the solvent proton signal as the standard. 
Dynamic light scattering (DLS) measurements were acquired using a Brookhaven 
Instruments (Worcestershire, U.K.) system, including a model BI-200SM goniometer, a 
model BI-9000AT digital correlator, a model EMI-9865 photomultiplier, and a model 95-
2 Ar ion laser (Lexel, Corp.; Farmindale, NY) operated at 514.5 nm.  Measurements were 
made at 25 ± 1 °C.  Prior to analysis, solutions were filtered through a 0.22 μm Gelman 
Nylon Acrodisc® 13 membrane filter to remove dust particles.  Scattered light was 
collected at a fixed angle of 90°.  The digital correlator was operated with 522 ratio 
spaced channels, and initial delay of 5 μs, a final delay of 100 ms, and a duration of 10 
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minutes.  A photomultiplier aperture of 400 μm was used, and the incident laser intensity 
was adjusted to obtain a photon counting of between, 200 and 300 kcps.  The calculations 
of the particle size distributions and distribution averages were performed with the ISDA 
software package (Brookhaven Instruments Co.), which employed single-exponential 
fitting, cumulants analysis, non-negatively constrained least-squares (NNLS) and 
CONTIN particle size distribution analysis routines.  The data are presented as the 
average values from at least four measurements. 
Transmission electron microscopy (TEM) measurements were conducted on a 
Hitachi H600 microscope.  Micrographs were collected at 100,000× magnification and 
calibrated using a 41 nm polyacrylamide bead from NIST.  Carbon-coated copper grids 
were treated with oxygen plasma prior to deposition of the micellar samples.  The 
samples were stained with 1% phosphotungstic acid (PTA) for 1 minute, and then the 
solution was wicked away and the samples were allowed to dry under ambient conditions.  
The number-average particle diameters (Dav) and standard deviations were generated 
from the analysis of a minimum of 100 particles from at least three different micrographs. 
Fast protein liquid chromatography (FPLC) was performed by Dr. Yongjian Liu in 
Prof. Michael J. Welch’s laboratory at Washington University School of Medicine on an 
AKTA (GE) system, including a P-920 pump, Columns of Superose 12 10/300 GL, and a 
UV detector with 254 nm wavelength.  The eluent was 20 mM HEPES with 150 mM 
NaCl and flow rate was 0.8 mL/min.  The results were analyzed by UNICORN 3.10.11. 
UV-vis spectra were acquired on a Varian Cary 1E UV-vis system (Varian, Inc., Palo 
Alto, CA) using polystyrene cuvettes. 
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Preparation of Cascade Blue and F3 Conjugated Micelles.  To two solutions of 
polymer 131 (30 mg 0.33 μmol) in DMF (10 mL) in 20 mL vials were added HBTU (18.5 
mg, 49 μmol) and HOBt (6.6 mg, 49 μmol).  The solutions were allowed to stir under 
argon for 1 h.  DIPEA (4 mg, 40 μmol) and Cascade Blue (1.54 mg, 2.5 μmol) were 
added subsequently to each solution.  The reaction mixtures were stirred under argon 
overnight.  F3 peptide (9.9 mg, 2.5 μmol) and FITC-F3 peptide (10.1 mg, 2.5 μmol) were 
added separately and the two reaction mixtures were stirred under argon for 48 h.  DMF 
(15 mL) was added to each vial to afford a 1.0 mg/mL solution (in polymer concentration) 
and the solutions were dialyzed (MWCO 6000-8000 Da) against nanopure water for 48 h 
to afford the micelle solution.  The micelle solutions were collected and were purified 
with Sephadex® G75 superfine column with 150 mM PBS (pH ~7.4) as the solvent, to 
remove unattached F3 peptide and cascade blue.  The purified micelle was washed with 5 
mM PBS (pH ~7.4) and concentrated by using Centricon tubes (MWCO 30000 a) and 
monitored by FPLC. 
Quantification of Cascade Blue (CB) was determined by UV-vis (400 nm, ε = 28000 
M-1cm-1, from manufacturer’s manual).  The conjugation of FITC-F3 was determined by 
UV absorbance from the FITC conjugated to F3 peptide (488 nm, ε = 39000 M-1cm-1 
determined by a calibration curve in 5 mM PBS, pH ~ 7.4).  Quantification of F3 
peptides was deduced from the coupling efficiency of FITC-F3 to the polymer by 
assuming that the two peptides had approximately the same coupling efficiency. 
Preparation of Cascade Blue and F3 (or scrambled F3) Conjugated, PEGylated 
Micelles.  To two solutions of polymer 131 (52 mg 0.57 μmol) in DMF (10 mL) were 
added HBTU (34.0 mg, 89 μmol) and HOBT (13.2 mg, 97 μmol).  The solutions were 
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allowed to stir under argon for 1 h.  DIPEA (10 mg, 100 μmol), NH2-PEO13-OMe (8.8 
mg, 12 μmol) and cascade blue (2.5 mg, 4.1 μmol) were added.  The reaction mixtures 
were stirred under argon overnight.  F3 (16.5 mg, 4.14 μmol) and scrambled F3 peptide 
(sequence: KDEARALPSQRSRKPAPPKPEPKPKKAPAKK) (16.4 mg, 4.10 μmol) 
were added and the reaction mixtures were stirred under argon for 48 h.  DMF (42 mL) 
was added to afford a 1.0 mg/mL solution (in polymer concentration) and the solution 
was dialyzed (MWCO 6000-8 000 Da) against nanopure water for 48 h.  The micelle 
solutions were collected and purified with Sephadex® G75 column with 150 mM PBS 
(pH ~7.4) as the solvent, to remove unattached F3 peptide, Cascade Blue and PEG chains.  
The purified micelle solutions were washed with 5 mM PBS (pH ~7.4) and concentrated 
by using Centricon tubes (MWCO 30000 Da) and monitored by FPLC.  A portion of the 
micelles was freeze-dried to powder to analyze the conjugation efficiency of PEGylation.  
NMRMn = 106 kDa.  1H NMR (300 MHz, DMSO-d6): δ 0.8-2.3 (br, m, CH2 and CH of 
backbone), 4.3-4.7 (s, br, CH2CF3, PhCH2), 6.4-7.5 (m, br, ArH), 8.2-8.4 (br, ArH of 
cascade blue), 8.6 (s, br, ArH of CB), 8.9-9.1 (m, br, ArH of CB), 12.0-12.5 (s, br, 
COOH) ppm. 
The conjugation of cascade blue (CB) was determined by UV-vis (400 nm, ε = 
28000 M-1cm-1 from manufacturer’s manual).  The conjugation of F3 and scrambled F3 
was calculated by assuming the same coupling efficiency achieved in the above 
experiments.  (488 nm, ε = 39000 M-1cm-1 in 5 mM PBS, pH ~ 7.4). 
General Procedures for Dox Loading.  A solution of Dox (2.7 mg mL-1 in CH2Cl2 
and 3 equivalent of triethylamine) was added to a micelle solution (4 mL,).  The weight 
percentage for the Dox loaded to the polymer was 30%. The solution was protected from 
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light and stirred with the container uncapped for 16 h.  The removal of unincorporated 
Dox was achieved using Centricon tubes (MWCO 30000 Da) and centrifuged at 3000 
rpm × 5 min.  After three cycles of washing and centrifuging, the filtrate was collected 
and analyzed by UV-vis (488 nm) to confirm the successful removal of the free Dox.  
The Dox-loaded micelle solutions were then reconstituted to a final volume of 4 mL.  The 
amount of incorporated Dox was determined by UV-vis (480 nm, ε = 12500 M-1cm-1 
determined by a calibration curve in DMF/PBS 4:1) in a 4:1 v/v mixture of DMF and 
Dox-micelle solution. 
In vivo studies on brain tumor mice with Dox-loaded micelles (performed by Dr. 
Zhiqiang Xu in Prof. Jeffrey R. Leonard at Washington University School of 
Medicine).  To mice with tumor established in the brain, micelles loaded with Dox were 
treated by retroorbital injection (twice per week, 0.5mg/kg DOX equivalent for high 
loading and 0.25mg/kg DOX equivalent for low loading, 5 mg/kg for free DOX) for 4 
weeks.  At the end of treatment mice were anesthetized and perfused with 4% 
paraformaldehyde by intracardiac injection.  Brain, heart, liver, kidney etc were then 
harvested and fixed with 4% paraformaldehyde before sent off for paraffin embedding 
and section.  For the immunohistochemistry staining, unstained slides were first 
processed for antigen retrieval using citrate buffer (pH=6.8).  Nucleus was counterstained 
with Hematoxin. 
 
Results and Discussion 
Amphiphilic hyperbranched polymers, constructed with a hyperbranched 
hydrophobic core and amphiphilic copolymer arms consisting of trifluoroethyl 
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methacrylate and acrylic acid residuals,31  were functionalized with cascade blue (CB) 
ethylene diamine and F3 peptide to afford the CB and F3 functionalized polymer 
(Scheme 3-1).  The coupling of CB and F3 peptide was achieved through amidation 
chemistry between the amino groups on the CB ethylene diamine or F3 peptide and the 
acrylic acid residues on the arms of the hyperbranched polymer, facilitated by HOBt and 
HBTU with DMF as the solvent.  After the conjugation, an appropriate amount of DMF 
was added to the reaction mixture to afford solutions with ca. 1 mg/mL.  The solutions 
were dialysed against nanopure water to remove DMF and other small molecule 
impurities and at the same time to form the micelles in water.  The micelles were further 
purified by running Sephadex® G75 columns, mainly to remove F3 peptides physically-
associated to the micelles which were not removed by dialysis.  FPLC analysis performed 
by Dr. Yongjian Liu showed improvement in sample purity after the column (Figure 3-1).  
The relative intensity of the peak at ca. 17.5 min from F3 peptide was greatly reduced.  
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Figure 3-1.  Representative FPLC traces of micelles conjugated with F3 
peptide before and after purification with Sephadex® G75 columns. 
 
CB was introduced as an optical tracer to localize the micelles while performing both 
in vitro cell internalization studies and in vivo tumor targeting studies.  The conjugation 
efficiency of CB was determined by UV-vis (400 nm, ε = 28000 M-1cm-1 from 
manufacturer’s manual). .The coupling efficiency of CB to the polymer was calculated to 
be around 70%.  Bradford assay to quantify the F3 targeting peptide with Coomassie Blue 
had been performed but no obvious color change was observed, possibly because the 
molecular weight of the peptide was too small (~ 3900 Da).32  To obtain the coupling 
yield of the peptide, a control experiment with similar conditions but using FITC-labeled 
F3 peptide was carried out.  The coupling efficiency of the FITC-F3 was then determined 
by measuring the UV absorption of the final micelle at 488 nm with a molar extinction 
coefficient 39000 M-1cm-1.  The coupling efficiency of F3 peptide (and later scrambled 
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F3 peptide) was assumed to be the same to that of the FITC-F3, which was around 50%.  
As a control, micelles prepared from the hyperbranched amphiphilic polymer 
functionalized only with CB was also prepared and characterized from the same methods.  
For micelles conjugated both with CB and F3, 6.9 CB molecules and 3.0 F3 molecules 
were attached to one polymer in average.  For micelles conjugated only with CB, ca. 5.8 
CB molecules were attached to one polymer.  Characterization data to these micelles are 
shown in Table 3-1.   
These micelles were then loaded with Dox using a similar procedure published 
previously.33  Dichloromethane was used as the organic solvent for Dox and also to swell 
the core of the micelle, facilitating the loading of the therapeutic.  The amount of Dox 
loaded in micelles was determined by UV-vis measurements.  The loading capacities for 
micelles 1 and 3 were 16 and 15 wt% based on the polymer mass, respectively (Table 3-
1). 
Table 3-1.  Summary of Characterization Data and Doxorubicin Loading for Micelles 
from F3- and/or CB- conjugated hyperbranched amphiphilic polymer. 
Sample DTEM nm 
Dh(n)a 
nm 
[polymer]
mg/mL 
F3/ 
polymerb
CB/ 
polymerb
Dox 
μg/mLb 
Loading 
capacity 
(wt%) 
1 7 ± 1 29 ± 4 0.609  5.8 99 16 
2 7 ± 1 28 ± 2 0.571  5.8   
3 7 ± 1 29 ± 2 0.636 3.0 6.9 96 15 
4 7 ± 1 29 ± 2 0.710 3.0 6.9   
a by DLS. b by UV-vis. 
 
To test if the F3 targeting peptide could enhance DOX delivery, DOX-loaded and/or 
F3-conjugated micelles (sample 1 and 3) were incubated with the U87MG cells and were 
studied by fluorescence imaging of the Dox (λmax: 480 nm) (These experiments were 
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performed by Dr. Zhiqiang Xu.).  As can be seen in Figure 3-2, an increased amount of 
DOX was incorporated into the nucleus for the targeted micelles (sample 3), while for the 
untargeted micelles (sample 1), most of the Dox was located surrounding the nucleus, 
suggesting an enhanced nuclear uptake of DOX in glioma cells induced by the 
incorporation of the F3 peptide.  At this time, it is not clear how F3 enhanced DOX 
delivery.  It’s hypothesized that with F3 targeting peptide, the nanoparticles could bind 
U87MG cell more efficiently and more strongly, leading to increased cell uptake, and as 
a result, more DOX was delivered. 
 
Figure 3-2.  Fluorescence images of DOX-loaded micelle without F3 (sample 1, left) and 
with F3 (sample 3, right) targeting peptide. 
 
A challenge in current brain cancer research is the difficulty for the therapeutics to 
cross the blood brain barrier (BBB) to reach the tumor tissues and cells. 8-11  Both TEM 
and DLS measurements have shown that these micelles had small sizes (DTEM = 7 ± 1 nm, 
Dh(DLS)num ~29 nm).  TEM images are shown in Figure 3-3 (poor quality due to 
difficulties in staining the samples). 
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A B
 
Figure 3-3.  Transmission electron microscopy (TEM) images of micelle nanoparticles 
conjugated with CB and F3 peptide.  A, sample 4, non-PEGylated; B, sample 5, 
PEGylated. 
 
To test if the targeted nanoparticles could pass the BBB in glioma-bearing mice, F3 
and CB conjugated micelles (sample 4) were administered into mice with U87MG tumor 
established by tail vein injection, and the untargeted micelle (sample 2) was used as the 
control.  With a specific polyclonal antibody against cascade blue, significantly larger 
amounts of staining within the tumor cells in the brain were detected (Figure 3-4, right), 
as compared with the control (Figure 3-4, left), indicating that F3 conjugated 
nanoparticles can indeed pass the BBB to reach the tumor cells and the presence of F3 
can facilitate the tumor targeting process.  In figure 3-3, the purple color indicates the  
 
 
Figure 3-4.  Immunohistochemistry (IHC) stains of brain tumor from U87MG xenograft 
mice treated with untargeted micelle (sample 2, left) and targeted micelle (sample 4, 
right). (IHC staining using specific antibody against cascade blue, ABC method.)  Scale 
bar: 10 μm. 
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presence of CB-functionalized micelle in the tumor cells.  These experiments were 
performed by Dr. Zhiqiang Xu. 
Dox-loaded micelles (samples 1 and 3) were administered by retroorbital injection, 
into mice implanted intracranially with tumors.  Brain, heart, liver, spleen and kidney 
tissues were harvested after the treatment.  Compared to untargeted micelles, targeted 
micelles were more concentrated within tumor-associated blood vessels (Figure 3-5, 
black arrow) while tumor cells adjacent to these blood vessels also showed significant 
amounts of micelles within their cytoplasm and nuclei (Figure 3-5, red arrow).  Some of 
these tumor cells showed fragmented DNA indicating apoptotic response (Figure 3-5, 
thick red arrow).  In contrast, untargeted micelles were distributed evenly among tumor 
cells and blood vessels, suggesting that this was mediated through non-specific leaky 
blood brain barrier (BBB).  Although targeted micelles showed promising binding to the 
tumor cells, it was found that significant amounts of the micelles were localized in the 
liver and spleen, suggesting that the biodistribution needs to be improved.  These 
experiments were performed by Dr. Zhiqiang Xu. 
 
 CB-DOX-NP CB-F3-DOX-NP CB-F3-DOX-NP 
Figure 3-5.  Immunohistochemistry (IHC) stains of brain tumor from U87MG 
xenograft mice treated with untargeted micelles (sample 1, left) and targeted 
micelles (sample 3, middle and right). (IHC staining using specific antibody 
against cascade blue, ABC method)  Scale bar: 10 μm. 
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Since the introduction of poly(ethylene glycol) was reported to enhance the 
biodistribution,34 PEGylated micelles were then synthesized (Scheme 3-1).  For our study, 
NH2-PEO16-OMe (MW = 750 Da) was selected with the concern that short PEO might 
have little hindering effects on the peptide binding.  Micelles with ca. 20 MeO-PEO16 
grafts per polymer were prepared, and conjugated with CB and F3 peptide (sample 5 in 
Table 3-2).  As a control, CB-conjugated and PEGylated micelles functionalized with a 
scrambled F3 peptide (sequence: KDEARALPSQRSRKPAPPKPEPKPKKAPAKK) 
were also prepared (sample 6 in Table 3-2).  The PEG contents of the two samples were 
ca. 14 wt%. 
Table 3-2.  Summary of Characterization Data and Doxorubicin Loading for Micelles 
from F3-CB-PEG750-Polymer. 
Sample DTEM nm 
Dh(n)a 
nm 
[polymer] 
mg/mL 
PEG 
per 
polymerb
F3 per 
polymerc
CB per
polymerc
Dox 
μg/mLc 
Loading 
capacity
(wt%) 
5 8 ± 1 28 ± 2 0.339 20 3.1 3.8 58 17 
6 7 ± 1 30 ± 2 0.250 20 3.1d 3.8 38 15 
a by DLS. b by 1H NMR. c by UV-vis. d scrambled F3 
(KDEARALPSQRSRKPAPPKPEPKPKKAPAKK). 
 
These two PEGylated samples were also administered to brain tumor bearing mice.  
As can be seen from figure 3-6, F3 conjugated targeting NPs were more concentrated in 
the angiogenic tumor blood vessels in the brain than scrambled F3 conjugated micelles, 
suggesting the targeting is a result of the specific binding of the F3 peptide to the tumor 
cells.  Compared to non-PEGylated NPs, slightly better biodistribution was obtained.  
Increasing the PEG content might be able to further enhance the biodistribution.34 
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  untargeted targeted 
Figure 3-6.  Immunohistochemistry (IHC) stains of brain tumor, xenografts of heart, lung, 
kidney and spleen, from U87MG mice treated with PEGylated NPs (untargeted, left, 
sample 6; targeted, right, sample 5). (IHC staining using specific antibody against 
cascade blue, ABC method)  Scale bar: 20 μm. 
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Conclusions 
In summary, micelle nanostructures have been assembled from a novel amphiphilic 
hyperbranched block copolymer and studied as a DOX delivery system to pass the blood 
brain barrier for treatment of brain tumors.  It was found that F3 peptide conjugated 
nanoparticles not only specifically bind to the tumor-associated angiogenic endothelial 
cells, doxorubicin carried by these nanoparticles also caused apoptotic effects on the 
targeted tumor cells.  PEGylation was found to enhance the biodistribution of these 
materials  This system showed potential to provide a novel approach to efficiently deliver 
therapeutics to targeted tumor sites, and also to potentially attenuate systemic side effects 
caused by free doxorubicin.  This nanoparticle system could be a good candidate for drug 
delivery applications.31  
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Chapter 4 
Labeling of Shell Crosslinked Nanoparticles (SCKS) for MRI 
Zicheng Li, Debasish Banerjee, Jie Zheng, Guorong Sun, Jinqi Xu, Joel R. Garbow, 
Pamela K. Woodard, Dennis A. Moore, Joseph J. H. Ackerman and Karen L. Wooley 
 
Abstract 
DOTAlysine-functionalized micelles and shell crosslinked nanoparticles (SCKs) 
were synthesized and labeled with gadolinium(III) for their development as nanoscale 
magnetic resonance imaging (MRI) contrast agents.  The chelating agent, DOTAlysine, 
was introduced onto the polymeric materials by either micelle/SCK post-modification or 
pre-conjugation onto the amphiphilic block copolymer precursors of the micelle/SCKs.  
The amphiphilic diblock copolymers PAA-b-PS (poly(acrylic acid)-b-polystyrene), with 
different block ratios, different block lengths, and with or without DOTA 
functionalization, were self-assembled into micelles and crosslinked intra-micellarly 
throughout their corona via amidation chemistry, upon reaction with 
2,2’-(ethylenedioxy)bis-ethylamine, to afford SCKs with different extents of 
crosslinking. 
 After the conjugation of Gd-DOTAlysine complex onto micelle/SCK nanoparticles, 
improved relaxivities were observed, compared to commercial contrast agents such as 
Magnevist (Gd-DTPA) and DOTAREM (Gd-DOTA).  The nanoparticles contributed to 
increase the rotational correlation lifetime of the Gd-DOTA.  Additionally, the highly 
hydrated nature of the poly(acrylic acid) shell layer in which the Gd-DOTAlysine was 
located allowed for rapid water exchange to achieve enhanced relaxation properties.  
The resulting materials exhibited large ionic relaxivities (40 mM-1s-1, at 40 　°C under 
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0.5 T).  In addition to the enhanced relaxivities, the properties of these nanoparticles, 
such as non-toxicity to mammalian cells and capability for polyvalent targeting, make 
them good candidates for utilization as nanoscale magnetic resonance imaging contrast 
agents within biological systems. 
 
INTRODUCTION 
Magnetic resonance imaging (MRI) is one of the widely used modalities for 
noninvasive medical diagnosis, which provides real-time high-resolution images of body 
tissues.  MRI measures the NMR signals of nuclei, mainly protons of water.  The 
differences in signal intensity can create contrast in the images, thereby enabling 
differentiation of the types of tissues and detection of disease states.1 
MRI has been advanced with the development of contrast agents (CAs) that provide 
more specific and clearer images and enlargements of detectable organs and systems, 
leading to a wide scope of applications of MRI not only for diagnostic radiology but also 
for therapeutic medicine.2  Current MRI contrast agents are in the form of either 
paramagnetic metal complexes or magnetic metal nanoparticles.3  In T1-weighted 
imaging, more intense signals are usually observed in regions with faster water proton 
longitudinal relaxation rates.  With the addition of paramagnetic metal complexes, such 
as gadolinium (GdIII) or manganese (MnII) complexes, the longitudinal (T1) relaxation of 
water protons can be accelerated and brighten contrast in regions where the complexes 
localization is exerted.4, 5  These paramagnetic metal complexes are also referred as 
positive contrast agents since more intense images are obtained.  Nowadays, 
approximate 30% of MRI investigations use a contrast agent.6  The majority of T1 
93
contrast agents currently used are stable complexes of gadolinium(III) (GdIII), which has 
seven unpaired electrons, making it the most paramagnetic among the stable metal 
ions.7-9  The slow relaxation of the GdIII electron spin is also an additional favorable 
factor.7  These complexes are usually ternary complexes of GdIII (such as Magnevist, the 
predominant contrast agent in commercial use today, which is comprised of a GdIII within 
the chelating ligand diethylenetriaminepentaacetic (DPTA)), in which the GdIII cation is 
complexed with a multidentate ligand (heptadentate or octodentate) and coordinated with 
water molecules.5, 10-13  The ligand is required for safety purposes, to ensure that the 
highly toxic GdIII sequestered in vivo and that the complex can be excreted intact, while 
the coordinated water molecules are required for contrast.  The GdIII ion relaxes the 
coordinated water molecules, which are in fast exchange with bulk water, resulting in a 
shortened T1 value for the bulk (and MRI observable) water.  The ability of the contrast 
agent to enhance the longitudinal relaxation rate (1/T1) of the solvent (mostly water) is 
referred as the longitudinal relaxivity R; see Equation  (1) in which Δ(1/T1) is the 
change in relaxation rate of the solvent after addition of contrast agent with metal 
concentration [M] in unit of mM.4 
R = 
][
)/1( 1
M
TΔ                                                      (1) 
At equal concentrations, a metal complex with enhanced relaxivity will appear 
brighter in an image compared to a complex of lower relaxivity; alternately a complex 
with higher relaxivity can provide the same contrast as a low relaxivity complex, but at a 
lower dose. 
Relaxivity can be factored into two terms that accounts for the relaxation effect due to 
the coordinated inner-sphere water molecules (RIS) and an outer-sphere term (ROS), which 
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encompasses contributions of relaxation to the second and outer-sphere water molecules.  
The relaxivity contributions from the directly coordinated inner-sphere water molecules 
usually weigh much more than that from the outer-sphere water molecules.  The 
inner-sphere relaxivity is given by Equation (3), which is derived from the description of 
two-site exchange.4, 14 
OSIS RRR +=                                                     (2) 
mM
IS
TOH
qR τ+= 12
1
][
                                               (3) 
Here q is the number of coordinated water molecules, the water concentration of 
water is in mM, T1m is the rotational correlation lifetime of the coordinated waters (s) and 
τm is the lifetime of the coordinated water molecules (inverse of the water-exchange rate, 
kex = 1/τm).  Optimal relaxivity of the GdIII complex is mainly dependent upon the two 
key features: the water-exchange rate (1/τm) and the rotational correlation lifetime T1m.15, 
16  Faster water exchange rate and longer rotational correlation life lead to enhanced 
relaxivities.  The water-exchange rate is currently under intense scrutiny in deployment 
and development of novel chelators, to which the GdIII is coordinated, and remarkable 
improvements have been observed compared to DTPA.17-21  While the rotational 
correlation lifetime has been found to increase through conjugation of the GdIII 
complexes to slowly tumbling macromolecular objects, including inorganic materials,22, 
23 dendrimers,15, 24, 25 polymers,26, 27 self-assembling materials,10, 28, 29 etc.  Due to the 
potential to display a large number of complexes in a confined volume and to 
simultaneously incorporate targeting/delivering functions, macromolecules and 
nanoparticles have been studied intensively as the scaffold for contrast agents.4, 5, 30, 31 
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In this study, a derivative of DOTA, DOTAlysine, was used as the chelator for GdIII 
to form Gd-DOTA complex.  Shell crosslinked nanoparticles (SCKs) were used as the 
nano-scale scaffold for the Gd-DOTA complex.  SCKs are self-assembled core-shell 
nanomaterials, originating from the crosslinking the shell domain of micelles assembled 
from amphiphilic block copolymers (poly(acrylic acid)-b-polystyrene (PAA-b-PS) in this 
work).  The SCKs obtained have a robust structure due to the covalent crosslinking 
reaction, and have controllable sizes ranging from 10 to 100 nm.10, 32-34  Gd-labeled 
SCKs also serve well for blood pool imaging, as a result of long circulation times, in 
contrast to their small molecular counterparts in which rapid clearance rates from the 
blood and passage into tissues prohibit blood pool imaging.34, 35  Additionally, the shell 
layer of the SCKs can be functionalized with targeting ligands such as folic acid,36 or 
peptides containing RGD motif as the αvβ3 integrin receptor antagonist,37 and cell 
penetrating peptide such as HIV-TAT PTD and PNA.38, 39  Nanoscale MRI contrast 
agents prepared from Gd-DOTA-functionalized SCK/micelles showed enhanced 
relaxivities over small molecule GdIII complexes.  In addition to the enhanced 
relaxivities, the properties of these nanoparticles, such as capability for polyvalent 
targeting, non-toxicity to mammalian cells and re-direction of biodistribution, make them 
good candidates for potential utilizations in biological systems. 
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Results and Discussion 
 To investigate and optimize the conditions and methodologies for labeling of the 
water-swollen shells of shell crosslinked knedel-like (SCK) nanoparticles, two synthetic 
approaches were carried out to afford micelles and SCKs functionalized with 
Gd-DOTAlysine complex (Scheme 4-1).  Strategy I was the straightforward 
post-labeling of GdIII onto nanoparticles pre-installed with DOTAs.  It included the 
preparation of DOTAlysine-grafted amphiphilic block copolymers, 
DOTAlysine-g-PAA-b-PS, followed by their self-assembly into micelles and shell 
crosslinking into SCKs.  The micelles and SCKs labeled with the DOTAlysine chelator 
were then loaded with GdIII to afford Gd-DOTAlysine labeled nanoparticles.  Strategy 
II was the pre-labeling of GdIII onto nanoparticles.  It involved the preparation of 
Gd-DOTAlysine functionalized amphiphilic block copolymers, 
Gd-DOTAlysine-g-PAA-b-PS, followed by micelles and SCKs formation.  The 
amphiphilic block copolymer used in this work, PAA60-b-PS35 was prepared through 
sequential atom transfer radical polymerization (ATRP) of t-butyl acrylate and styrene to 
afford poly(tert-butyl acrylate)-b-polystyrene (PtBA-b-PS), followed by acidolysis with 
trifluoroacetic acid in dichloromethane to remove the t-butyl ester protecting groups.34  
Synthesis of the chelator to Gadolinium, DOTAlysine, was reported previously.34 
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 DOTAlysine was attached to PAA60-b-PS35, via amidation chemistry between the 
amino groups on the lysine and the carboxyl groups along the PAA block.  The 
reaction was conducted in anhydrous DMF.  EDCI and HOBt were added to activate 
the carboxylic acid groups on the PAA block.  DOTAlysine and DIPEA were then 
added as a DMF solution.  The purification was then performed by dialysis against 
nanopure water to remove small molecular impurities.  The obtained aqueous 
polymer solution was lyophilized to afford DOTAlysine-grafted PAA60-b-PS35.  Two 
polymers with average numbers of 4.0 and 7.0 DOTAlysine molecules per polymer 
chain (obtained from 1H NMR spectroscopy analysis), DOTAlysine4-g-PAA56-b-PS35 
and DOTAlysine7-g-PAA53-b-PS35, were synthesized. 
Micellizations of the above two block copolymer precursors and crosslinking 
reactions were carried out through “conventional” protocols to assemble 
nanostructures.  Nanopure water, a selective solvent for the DOTAlysine-g-PAA 
block segment, was added gradually to the copolymer solution in DMF (a common 
solvent for both the hydrophilic and hydrophobic blocks, ~ 1.0 mg/mL) until 50 wt% 
of water content was reached.  Finally, the organic solvent was removed through 
extensive dialysis again water to afford micelles in aqueous media.  These micelles 
were stabilized by covalently crosslinking the shell PAA domain with 
2,2’-(ethylenedioxy)-bis(ethylamine) mediated by EDCI to afford the SCKs.  Small 
molecule impurities were again removed by dialysis.  SCKs with nominal 20% and 
50% crosslinking extents were prepared from both micelles.  The final polymer 
concentrations for these nanoparticles were ca. 0.25 mg/mL. 
 Characterizations of the micelles and SCKs by transmission electron microscopy 
(TEM) revealed globular shapes of these nanostructures with number-averaged TEM 
diameters (Dav) of 13 ± 1 nm and 12 ± 1 nm, assembled from 
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DOTAlysine7-g-PAA53-b-PS35, and DOTAlysine4-g-PAA56-b-PS35, respectively.  
Figure 4-1 shows the TEM images for the micelle and 50% crosslinked SCKs 
prepared from DOTAlysine7.0-g-PAA53-b-PS35.  No discernable Dav differences were 
observed between micelles and SCKs.  The number-averaged hydrodynamic 
diameters (Dh, n) for these nanoparticles were determined by dynamic light scattering 
(DLS) and were measured as 21 ± 3 nm.  The aggregation number, which is defined 
as the average number of polymer chains in one nanoparticle, was calculated from the 
Dav of the nanoparticles based upon the fact that only the PS core domains were 
visualizable by TEM (after negatively staining) according to the following equation: 
A
n
av
aggr NM
D
N ⋅
⎟⎠
⎞⎜⎝
⎛⋅
=
3
23
4 πρ
                                             (4) 
where Naggr is the aggregation number, ρ is the density of PS block (1.05 g/cm3), Dav 
is the average TEM diameter of the nanoparticles, Mn is the molecular weight of the 
PS block and NA is Avogadro’s constant ( 2310022.6 ×  mol-1). 
 
Figure 4-1.  Transmission electron micrographs of A) micelle prepared from 
DOTAlysine7-g-PAA53-b-PS35 and B) 50% crosslinked SCKs from 
DOTAlysine7-g-PAA53-b-PS35, each as a dry sample upon a carbon-coated copper 
grid and negatively stained with 1 wt% of phosphotungstic acid (PTA).  Scale bar 
denotes 100 nm. 
 
A B 
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 To form the nanoscale MRI contrast agents, the micelles and SCKs prepared from 
DOTAlysine7-g-PAA53-b-PS35 were incubated with GdCl3 aqueous solution 
(N(DOTA) : N(GdIII) = 1 : 2) at 60 °C for 6 h.  Exhaustive dialysis of the reaction 
mixtures into presoaked dialysis tubings (MWCO 6,000-8,000 Da) against nanopure 
water (pre-treated with Chelax® 100 to remove any heavy metal present) was carried 
out to remove free GdIII ions to afford Gd-DOTAlsyine-micelles and SCKs as the 
nanoscale magnetic resonance contrast agents (Post-Gd-DOTA-Micelle/SCKs).  
TEM and DLS characterizations of these nanoparticles showed almost no particle size 
variations from the corresponding precursors.  Concentrations of GdIII were then 
determined by inductively coupled plasma-mass spectrometry (ICP-MS), using 
standard InIII and TbIII solutions as the internal standards.  According to GdIII 
measured concentrations, the GdIII coupling efficiency to DOTAlysine was between 
75% and 85%, i.e., 75%-85% of the DOTAlysine molecules were complexed with 
GdIII. 
The governing water relaxation linear relationship was described as equation 4. 
    R1 = R × [GdIII] + R10                                             (5) 
where R is relaxivity (mM-1s-1), R1 and R10 are the water relaxation rate constants (s-1) 
with and without the relaxation agent, respectively, and [GdIII] is the concentration of 
relaxation agent in mM.   
Proper amounts of D2O were then added to the nanoparticles functionalized with 
Gd-DOTAlysine to prepare the nanoparticle relaxation agents in a H2O:D2O mixture 
(90/10 v/v).  The presence of D2O allows the use of a field/frequency lock as 
generally required on high field analytical NMR spectrometers and it will not interfere 
with relaxation determinations at low field where a field/frequency lock is not 
generally required.  For each micelle/SCK functionalized with Gd-DOTAlysine, a 
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series of dilutions with different GdIII concentrations in H2O:D2O (90/10 v/v) were 
prepared.  Water relaxation constants (R1) to these dilutions were measured by the 
inversion recovery pulse sequence at multiple agent concentrations.  The measured 
R1 constants were plotted vs. [GdIII] and the data were fit to a straight line as per 
above equation (example shown in Figure 4-2).  The slope yields R with units of 
mM-1s-1.  As a note, the data were expressed as R per mM GdIII, not R per mM 
nanoparticle, i.e., the ionic relaxivity.  Each rate constant R1 was measured in 
triplicate.  The water relaxation constants were measured by Dr. Debasish Banerjee. 
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Figure 4-2  Representative plot of rate constant vs. [Gd] 
 
 
The T1 relaxivities (R) of the 20% and 50% crosslinked SCKs from 
DOTAlysine7-g-PAA53-b-PS35 were tested at field strengths of 4.7, 3.0 and 1.5 T, at 
room temperature (Table 4-1).  Compared to Gd-DOTAlysine, whose relaxivity 
value at room temperature under 1.5 T was determined as 3.9 mM-1s-1, the maximum 
relaxivity, obtained from 20% crosslinked Gd-DOTA-SCK conjugates (prepared from 
DOTAlysine7-g-PAA53-b-PS35 and loaded with ca. 530 GdIII per SCK), was 60 
mM-1s-1 per GdIII, in the same field strength at room temperature, ca. 15-fold higher 
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than that of Gd-DOTAlysine.  As mentioned previously, and demonstrated here, the 
incorporation of lanthanide complexes into a macromolecular structure has been 
shown to improve relaxivity due to the slow tumbling rate of the macromolecular 
structures.  Also, as expected, the relaxivities of the SCKs increased as the field 
strengths decreased, since it is well known that T1 relaxivity typically decreases with 
increasing field strength for slow tumbling contrast agents.40, 41  No appreciable 
changes in the ionic relaxivity were found between 20% and 50% crosslinked SCKs 
functionalized with Gd-DOTAlysine.  Also, with the larger number of Gd ions on 
each nanoparticle, these materials showed very large molecular relaxivities, 33,100 
mM-1s-1 and 46,700 mM-1s-1 under 1.5 T for the 20% and 50% crosslinked 
SCKs ,respectively. 
Table 4-1.  Relaxivity values collected under different field strengths for 20% and 50% crosslinked SCK 
nanoscale contrast agents prepared from DOTAlysine7-g-PAA53-b-PS35. (Post-Gd-DOTA-Micelle/SCKs) 
RGda (mM-1s-1) RSCKb (mM-1s-1) 
entry extent of crosslinking 
Dav(TEM)
nm Naggr.
# Gd 
per 
SCK 4.7 T 3.0 T 1.5 T 4.7 T 3.0 T 1.5 T
A 20% 13±1 205 529 21.3 34.2 62.7 11200 18100 33100
B 50% 13±1 205 826 20.9 30.9 56.6 17200 25500 46700
a T1 relaxivity per mM of GdIII.  b Relaxivity per mM of SCK. 
 
However, it was found that about six months after the preparation of the above 
SCK nanoscale contrast agents, free GdIII ions were detected by Arsenazo III 
(2,2’-(1,8-dihydroxy-3,6-disulfonaphthylene-2,7-bisazo)dibenzenearsonic acid) test 
(Arsenazo III gives unique UV-vis absorbance spectrum (λmax ~650 nm) in the 
presence of free GdIII ions) (Figure 4-3).10, 11  The peak that appeared at 654 nm 
indicated the presence of free or loosely bound GdIII ions.  Since the shell layer of 
the SCKs is comprised predominantly of amides, acids, and ether subunits, the SCKs 
might also bind GdIII ions.  However, compared to Gd-DOTAlysine, whose stability 
constant is in the range of 1 × 10 25 M-1 at neutral pH values, the binding of GdIII ions 
to the shell of the SCKs are weak and are readily dissociated from the SCKs.10, 42,43 
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Figure 4-3.  UV-vis spectra of Arsenazo III test: the dashed spectrum is of the neat 
Arsenazo III aqueous solution; the solid spectrum is of the reaction mixture of 
Arsenazo III and 20% crosslinked SCKs from DOTAlysine7-g-PAA53-b-PS35.  The 
appearance of the peak at 654 nm showed the presence of free GdIII ions. 
 
The presence of free or weakly bound GdIII ion is a significant problem for in 
vivo applications of these nanomaterials, for instance in MRI, due to its high 
toxicicity,44  To remove free or weakly bound GdIII ion, the reaction mixtures were 
treated with DTPA (diethylenetriaminepentaacetic acid) to challenge GdIII ions not 
chelated with DOTAlysine, followed by exhaustive dialysis in presoaked dialysis 
tubings (MWCO 6,000-8,000 Da) against nanopure water.  The Gd-DTPA complex 
was reported to have a similar stability constant as Gd-DOTA.42  By this method, 
micelles, and 20% and 50% crosslinked SCKs loaded with Gd-DOTAlysine were 
prepared (table 4-2).  Arsenazo III tests of the nanoparticle solutions showed 
“negative” results, demonstrating that no free or weakly bound GdIII ions were present.  
Table 4-2 showed the T1 relaxivity values of these three nanoscale MR contrast agents 
at room temperature under 4.7, 3.0 and 1.5 T.  Although these materials were clean 
from free GdIII ions, the ionic relaxivity values decreased drastically compared to the 
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above materials that had not undergone DTPA challenge.  The maximum ionic 
relaxivity was only 21.5 mM-1s-1 under 1.5 T, while it was 62.7 mM-1s-1 for the first 
set of nanoparticles not treated with DTPA.  Also, similar relaxivity values were 
observed for each sample under the three different field strengths.  It was reported 
that for small, fast tumbling molecules such as Gd-DTPA, T1 relaxivity showed 
almost no change while increasing field (3.4, 3.3, 3.1, 3.2 mM-1s-1 under 4.7 T, 3.0 T, 
1.5 T and 0.5 T, respectively).45-47  Therefore, we hypothesized that the presence of 
non-covalently bound Gd-DTPA had caused the similar relaxivities under different 
fields, since the interaction between the various functionalities in the PAA shell of the 
nanoparticles and DTPA can make the complete removal of Gd-DTPA via dialysis 
difficult. 
 
Table 4-2.  Relaxivity values measured under different field strengths for micelles, 20% and 50% crosslinked 
SCK nanoscale contrast agents prepared from Post-DOTAlysine4-g-PAA56-b-PS35.  DTPA was used to remove 
GdIII not chelated to DOTAlysine.  (Post-Gd-DOTA-Micelle/SCKs) 
RGda (mM-1s-1) RSCKb (mM-1s-1) 
entry extent of crosslinking 
Dav(TEM)
nm Naggr.
# Gd 
per 
SCK 4.7 T 3.0 T 1.5 T 4.7 T 3.0 T 1.5 T
C 0 12±1 162 660 10.7 16.4 21.5 7120 10900 14300
D 20% 12±1 162 310 7.9 9.8 11.0 2400 3000 3140
E 50% 12±1 162 280 8.9 10.8 12.5 2500 3020 3500
a T1 relaxivity per mM of Gd.  b Relaxivity per mM of SCK. 
 
 To solve these problems encountered (presence of free GdIII ions without DTPA 
challenge and complications that originated from the DTPA challenge), and to 
generate “clean” nanoscale contrast agents, strategy II was applied.  In this strategy, 
block copolymers covalently labeled with Gd-DOTAlysine complex were first 
prepared (Gd-DOTAlysine-g-PAA-b-PS), from which micelles were assembled and 
SCKs were then constructed.  To afford Gd-DOTAlysine-g-PAA-b-PS, two methods 
were performed, as shown in scheme 4-2.  Method A involved the preparation 
DOTAlysine-g-PAA-b-PS through the previous methods (vide supra), followed with 
GdIII loading by incubating the polymer solution with the solution of GdCl3 in DMF at 
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room temperature; dialysis of the reaction mixture in presoaked dialysis tubing 
(MWCO 6-8000 Da) against nanopure water was carried out and the polymer was 
obtained after lyophilization.  Method B entailed the preparation of Gd-DOTAlysine 
complex first, and the complex was then covalently attached onto PAA-b-PS via 
carbodiimide-mediated amidation chemistry in DMF.  The final functionalized block 
copolymer precursors were obtained after dialysis purification and lyophilization.   
 From method A, a series of DOTAlysine-grafted polymers were synthesized with 
averages of 2.3, 3.0, 3.8, and 8.0 DOTAlysines per polymer chain, respectively, as 
determined by 1H NMR spectroscopy.  By method B, 
Gd-DOTAlysine1.3-g-PAA58.7-b-PS35 was prepared and the numbers of 
Gd-DOTAlysine units per polymer were determined by ICP-MS (the presence the 
paramagnetic GdIII ions affected 1H NMR quantification).  
Pre-Gd-DOTA-Micelle/SCKs were then prepared from the corresponding 
Gd-DOTAlysine-g-PAA-b-PS precursors, with varying numbers of DOTAs per 
nanostructure and different extents of crosslinking.  Results from the Arsenazo-III 
test indicated that these materials were clean from free or weakly bound GdIII ions.   
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At different temperatures and under different field strengths, both T1 and T2 
relaxivity values for these materials were determined by the inversion recovery pulse 
sequence at multiple agent concentrations (Table 4-3) (Relaxivities under 0.5, 1.5 and 
4.7 T were measured by Dr. Debasish Banerjee.  Relaxivities under 3.0 T were 
measured by Dr. Jie Zheng).  For the micelle samples, except for sample K, all  
micelles with approximately 1.0 GdIII per polymer chain, i.e., samples E, F, H and M, 
showed similar T1 relaxivities under the same measuring conditions, around 27 
mM-1s-1 under 0.5 T at 40 ºC, no matter through synthetic method A or B.  These 
results indicated that there was no obvious difference between the two preparation 
methods regarding to the relaxivity values achieved.  Micelle K, whose precursor 
had more GdIII content, 2.1 GdIII per polymer chain, showed slightly larger T1 
relaxivities than micelles with ca. 1.0 Gd per polymer chain.  Theoretically, the 
relaxivities are independent with GdIII concentrations and for our case, it was 
speculated that parts of the GdIII ions on the nanoparticles might be strictly confined 
inside certain small spaces and the water molecules were not quite accessible to these 
GdIII ions.  For Gd-based MR contrast agents, two key factors to enhance the T1 
relaxivity are increase of the water exchange rate and increase of the rotational 
correlation time.  Samples prepared from polymers with more numbers of GdIII per 
chain could have relatively more GdIII that were in an environment with good water 
accessibility and had faster water exchange rates, thus leading to relatively larger 
relaxivities. 
 Again, for each sample, the T1 relaxivities decreased as the field strength 
increased.  It’s also observed that under the same field strength, higher T1 
relaxivities were obtained at lower temperatures.  This can be explained by the fact 
that at lower temperatures, the tumbling rates of the nanoparticles is reduced and leads 
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to a long rotational correlation lifetime of the Gd-DOTAlysine complex, which 
further provides enhanced T1 relaxivity.  It was also observed that under the same 
measuring conditions, T1 relaxivities for nanoparticles increased as the extent of 
crosslinking increased (from micelle to 20% crosslinked SCKs to 50% crosslinked 
SCKs).  One possible explanation was that the crosslinking throughout shell domain 
of the micelles inhibited the movement (mainly rotation) of the Gd-DOTAlysine as 
well and resulted in an elongated rotational correlation time.  The maximum T1 
relaxivity, obtained from 50% crosslinked Pre-Gd-DOTA-SCK conjugates (sample L, 
prepared from Gd1.6-DOTA8.0-g-PAA52-b-PS35), was 39.6 mM-1s-1 per Gd, in an 
applied magnetic field 0.5 T at 40 °C, ca. 11-fold higher than that of Gd-DOTAlysine 
(3.4 mM-1s-1).  For the T2 relaxivities, these nanoparticular contrast agents also 
showed enhanced values compared with Gd-DOTA (in the range from 3.2 to 4.1 
mM-1s-1 under 0.5-4.7 T).45  The trend of increasing T2 relaxivities with increasing 
extents of crosslinking was also observed, but the influences from temperatures and 
field strengths on T2 relaxivities were minor in comparison with the effects on T1 
relaxivities.
109
T
ab
le
 4
-3
. 
 R
el
ax
iv
ity
 v
al
ue
s 
at
 d
iff
er
en
t 
te
m
pe
ra
tu
re
s 
an
d 
va
rio
us
 f
ie
ld
 s
tre
ng
th
s 
fo
r 
Pr
e-
G
d-
D
O
TA
-M
ic
el
le
/S
C
K
 
na
no
sc
al
e 
M
R
 c
on
tra
st
 a
ge
nt
s. 
                    
  
a 
T 1
 re
la
xi
vi
ty
 p
er
 m
M
 o
f G
dI
II .
 
 
R
el
ax
iv
iti
es
 (m
M
-1
s-1
)a  
0.
5 
T 
1.
5 
T 
3.
0 
T 
4.
7 
T
40
 °C
22
 °C
 
37
 °C
 
22
 °C
 
37
 °C
 
40
 °C
sa
m
pl
e 
# 
D
O
TA
 
pe
r 
po
ly
m
er
 
ch
ai
n 
#G
d 
pe
r 
ch
ai
n 
Pr
ep
ar
at
io
n 
m
et
ho
d 
Ex
te
nt
 o
f 
cr
os
sl
in
ki
ng
T 1
 
T 1
 
T 2
 
T 1
 
T 2
 
T 1
 
T 2
 
T 1
 
T 2
 
T 1
 
D
TE
M
 
(n
m
) 
F 
2.
3 
1.
0 
A
 
0 
(m
ic
el
le
) 
27
.0
 
25
.5
1 
42
.5
1 
23
.3
7 
48
.0
3 
16
.4
9
44
.2
9
14
.5
 
46
.1
4
8.
7 
11
±1
 
G
 
3.
8 
1.
4 
A
 
0 
(m
ic
el
le
) 
26
.8
 
16
.3
4 
22
.8
1 
14
.9
5 
24
.4
4 
11
.6
2
22
.2
7
9.
63
 
21
.0
2
10
.1
 
11
±1
 
H
 
3.
0 
1.
3 
A
 
0 
(m
ic
el
le
) 
22
.2
 
18
.3
2 
24
.7
7 
16
.3
7 
23
.7
6 
16
.5
2
24
 
16
.0
8
20
.2
3
10
.3
 
18
±1
 
I 
3.
0 
0.
91
 
A
 
20
 %
 
35
.6
 
28
.5
6 
39
.4
8 
24
.2
3 
41
.1
4 
24
.0
4
40
.5
 
18
.1
2
41
.9
 
16
.8
 
18
±1
 
J 
3.
0 
0.
84
 
A
 
50
 %
 
38
.7
 
29
.5
7 
44
.3
6 
25
.3
 
42
.3
 
23
.9
 
42
.0
6
12
.0
7
37
.8
8
15
.1
 
18
±1
 
K
 
8.
0 
2.
1 
A
 
0 
(m
ic
el
le
) 
35
.0
 
27
.2
4 
41
.5
8 
22
.8
4 
39
.5
9 
19
.5
1
40
.7
9
18
.2
7
37
.2
6
13
.8
 
15
±1
 
L 
8.
0 
1.
6 
A
 
50
 %
 
39
.6
 
31
.7
1 
45
.1
3 
26
.5
3 
43
.0
4 
23
.8
2
44
.3
3
19
.1
3
38
.4
4
15
.4
 
15
±1
 
M
 
1.
3 
1.
3 
B
 
0 
(m
ic
el
le
) 
27
.1
 
24
.4
6 
36
.1
6 
20
.5
9 
36
.4
 
16
.1
4
34
.1
 
14
.6
3
31
.3
9
7.
4 
14
±2
 
N
 
1.
3 
1.
3 
B
 
20
 %
 
34
.7
 
30
.2
9 
43
.2
 
25
.7
1 
41
.2
 
21
.9
8
41
.1
7
18
.1
 
37
.4
3
8.
1 
14
±2
 
O
 
1.
3 
1.
3 
B
 
50
 %
 
36
.7
 
32
.3
2 
42
.1
3 
26
.6
1 
43
.3
1 
22
.2
1
38
.3
5
19
.0
9
36
.5
7
7.
1 
14
±2
 
110
Experimental Section 
Materials 
 All solvents were purchased from Sigma-Aldrich and were used without further 
purification unless otherwise noted.  Trifluoroacetic acid (TFA; 95%; Aldrich), 
2,2′-(ethylenedioxy)-bis(ethylamine) (97%; Aldrich), 
1-(3′-dimethylaminopropyl)-3-ethylcarbo-diimide methiodide (EDCI; 98%; Aldrich), 
palladium on carbon (10 wt% loading; Aldrich), were used as received.  
DOTAlysine(tetra t-butyl ester) was provided by Dr. Dennis A. Moore at Covidien 
Inc., Saint Louis, MO.  Diehthylenetriaminepentaacetic acid (DTPA, >99%) was 
purchased from Aldrich.  Gadolinium chloride (GdCl3; 99.99%) was purchased from 
Aldrich and used as received.  Supor 25 mm 0.1 μm Spectra/Por Membrane tubes 
(molecular weight cutoff (MWCO) 3,500 or 6-8000 Da), purchased from Spectrum 
Medical Industries Inc., were used for dialysis.  Nanopure water (18 MΩ⋅cm) was 
acquired by means of a Milli-Q water filtration system (Millipore Corp.; Bedford, 
MA).  Chelax® 100 resin was purchased from Bio-Rad Laboratories, Inc., CA, and 
was to remove heavy metal present in all the aqueous solvent used in this work. 
 5 mM PBS (phosphate buffered saline, with 5 mM of phosphates and 5 mM of 
NaCl) was prepared by mixing NaH2PO4 (0.76 g), Na2HPO4 (1.93 g) and NaCl (1.17 
g) into 4 liters of nanopure water and has a pH ~7.4. 
Instrumental 
1H NMR spectra were recorded on a Varian 300 MHz spectrometer interfaced to 
a UNIX computer using Mercury software.  Chemical shifts are referred to the 
solvent proton resonance.  Infrared spectra were acquired on a Perkin-Elmer 
Spectrum BX FT-IR instrument using KBr pellets. 
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Absolute molecular weight and molecular weight distribution were determined by 
Gel Permeation Chromatography (GPC).  GPC was performed on a Waters 1515 
HPLC system (Water Chromatography Inc., Medford, MA), equipped with a Waters 
2414 differential refractometer, a PD2020 dual-angle (15 ° and 90 °) light scattering 
detector (Precision Detector, Inc.), and a three-column series PL gel 5 μm Mixed 
columns (Polymer Laboratories Inc.).  The system was equilibrated at 35  °C in 
anhydrous THF, which served as the polymer solvent and eluent (flow rate set to 1.00 
mL/min then determined gravimetrically).  All instrumental calibrations were 
conducted using a series of nearly monodispersed polystyrene standards.  Data were 
collected upon an injection of a 200 μL of polymer solution in THF (ca. 5.0 mg/mL), 
and then analyzed using Discovery 32 software (Version, Precision Detectors Inc).  
Inter-detector delay volume and the light scattering detector calibration constant were 
determined by calibration using a nearly monodispersed polystyrene standard 
(Pressure Chemical Co., Mp = 90 kDa, Mw/Mn < 1.04).  The differential 
refractometer was calibrated with standard polystyrene reference material (SRM 706 
NIST), of known specific refractive index increment dn/dc (0.184 mL/g).  The dn/dc 
values of the analyzed polymers were then determined from the differential 
refractometer response. 
Differential scanning calorimetry (DSC) measurements were performed with a 
DSC822e instrument (Mettler-Toledo, Inc.) in a temperature range of – 100 to 180 °C 
with a ramp rate of 10 °C/min under nitrogen.  Data were acquired and analyzed 
using STARe software (Mettler-Toledo, Inc.).  The glass transition temperature, Tg, 
was determined at the midpoint of the inflection tangent upon the third heating scan. 
Samples for transmission electron microscopy (TEM) measurements were diluted 
with 1 wt% of phosphotungstic acid (PTA) stain solution (v/v, 1:1).  Carbon grids 
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were exposed to oxygen plasma treatment to increase the surface hydrophilicity.  
Micrographs were collected at 100,000 magnifications.  The number average particle 
diameters (Dav) and standard deviations were generated from the analysis of a 
minimum of 150 particles from at least three different micrographs.  
The average heights for the nanoparticles were determined by performing 
tapping-mode AFM under ambient conditions in air.  The AFM instrumentation 
consisted of a Nanoscope III BioScope system (Digital Instruments, Veeco Metrology 
Group; Santa Barbara, CA) and standard silicon tips (type, OTESPA-70; L, 160 μm; 
normal spring constant, 50 N/m; resonance frequency, 246-282 kHz).  Samples for 
AFM imaging analysis were prepared through spin-coating ca. 2.0 μL of the 
nanoparticle solution (typical concentration: 0.2 mg/mL) onto freshly cleaved mica 
plates (Ruby clear mica, New York Mica Co.) and allowed to dry freely in air.  The 
number-average particle heights (Hav) values and standard deviations were generated 
from the sectional analysis of more than 150 particles from several different regions. 
Hydrodynamic diameters (Dh) and size distributions for the SCKs in aqueous 
solutions were determined by dynamic light scattering (DLS).  The DLS instrument 
consisted of a Brookhaven Instruments Limited (Worcestershire, U.K.) system, 
including a model BI-200SM goniometer, a model BI-9000AT digital correlator, a 
model EMI-9865 photomultiplier, and a model 95-2 Ar ion laser (Lexel Corp., 
Farmindale, NY) operated at 514.5 nm.  Measurements were made at 20 　°C.  
Prior to analysis, solutions were filtered through a 0.22 μm Millex GV PVDF 
membrane filter (Millipore Corp., Medford, MA) and then centrifuged in a model 
5414 microfuge (Brinkman Instruments, Inc., Westbury, NY) for 10 minutes to 
remove dust particles.  Scattered light was collected at a fixed angle of 90 °.  The 
digital correlator was operated with 522 ratio spaced channels, and initial delay of 5 
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μs, a final delay of 100 ms, and a duration of 10 minutes.  A photomultiplier aperture 
of 400 μm was used, and the incident laser intensity was adjusted to obtain a photon 
counting of between 200 and 300 kcps.  Only measurements in which the measured 
and calculated baselines of the intensity autocorrelation function agreed to within 
0.1% were used to calculate particle sizes.  The calculations of the particle size 
distributions and distribution averages were performed with the ISDA software 
package (Brookhaven Instruments Company), which employed single-exponential 
fitting, cumulants analysis, non-negatively constrained least-squares (NNLS) and 
CONTIN particle size distribution analysis routines.  All determinations were made 
in triplicate. 
Gadolinium concentrations were determined by inductively coupled plasma-mass 
spectrometry.  Measurements were performed on a 7500ce Agilent, quadrupole mass 
spectrometer, equipped with an octapole reaction cell for removal of polyatomic 
interferences, and using 2% HNO3 as the matrix.  TlIII and InIII standard solutions 
purchased from Aldrich were used as the internal standards.  All determinations 
were made in triplicate. 
UV-vis spectra were acquired on a Varian Cary 1E UV-vis system (Varian, Inc., 
Palo Alto, CA) using polystyrene cuvettes. 
Measurements of relaxation times at 3 T were performed by Prof. Jie Zheng at 
Washington University School of Medicine.  Measurements of relaxation times at 
0.5 T, 1.5 T and 4.7 T were performed by Dr. Debasish Banerjee (former Postdoc 
associate in Prof. Joseph J. H. Ackerman’s laboratory at Washington University 
School of Medicine).  All measurements were performed in triplicate. 
Experimental 
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 Syntheses of DOTAlysine, PAA60-b-PS35, DOTAlysine-grafted PAA60-b-PS35, 
and micelle/SCK preparation from these polymers were described before by Dr. Jinqi 
Xu (former Postdoc associate in Prof. Karen L. Wooley’s laboratory at the 
Department of Chemistry of Washington University).34 
General Procedure for DOTAlysine-g-PAA-b-PS Synthesis: Grafting 
DOTAlysine onto PAA-b-PS by amidation involved the following: To a 
round-bottom flask equipped with a magnetic stir bar, was added a sample of 
PAA-b-PS block copolymer and anhydrous N,N-dimethylformamide (DMF).  The 
mixture was stirred for 1 h at room temperature to ensure that a clear and 
homogeneous solution was obtained.  To this solution, was added 
1-[3′-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide (EDCI) and 
1-hydroxybenzotriazole (HOBt) and the reaction mixture was stirred for 1 h at room 
temperature.  Finally, a pre-mixed solution of DOTAlysine (as a TFA salt) and 
N,N-diisopropylethylamine (DIPEA) in anhydrous DMF was added and the reaction 
mixture was further stirred for 20 h at room temperature.  The reaction mixture was 
then transferred to pre-soaked dialysis tubing (MWCO ca. 6000 to 8000 Da) and 
dialyzed against nanopure H2O (18.0 MΩ⋅cm, pre-treated with Chelex100) for 4 d to 
remove the organic solvent and small molecule by-products. The aqueous solution 
was then lyophilized to afford the product as white solid.  The numbers of 
DOTAlysine molecules per polymer chain were determined by 1H NMR spectroscopy 
analyses.  The DOTAlysine coupling yields were determined to be larger than 85%. 
General Procedures for Micelle Formation.  To a solution of 
DOTAlysine-g-PAA-b-PS diblock copolymer in THF (ca. 1.0 mg/mL), an equal 
volume of nanopure H2O was added dropwise via a syringe pump over 6 h.  The 
reaction mixture was further stirred for ca. 16 h at room temperature before 
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transferring to a presoaked dialysis tubing (MWCO ca. 6,000-8,000 Da), and dialyzed 
against nanopure H2O for 4 days, to afford a micelle solution with the final polymer 
concentration of  0.20-0.30 mg/mL. 
General Procedures for the Crosslinking of PAA Block to Form SCKs.  To 
a solution of micelle in nanopure H2O, was added dropwise a solution of 
2,2’-(ethylenedioxy)bis(ethylamine) (ca. 1.0 mg/mL) in nanopure H2O over 10 min.  
The reaction mixture was stirred for ca. 2 h at room temperature.  To this solution, 
was added dropwise via syringe pump over 30 min, a solution of 
1-[3’-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide in nanopure H2O.  
The reaction mixture was further stirred 20 h at room temperature before transferring 
to a presoaked dialysis tubing (MWCO ca. 6,000-8,000 Da), and dialyzed against 
nanopure H2O for 4 days, to remove all of the impurities and afford the SCK solution.  
The nominal crosslinking extent (20% and 50%) were based on the stoichiometry of 
the crosslinker (2,2’-(ethylenedioxy)bis(ethylamine)) to that of the carboxylic acids 
on the PAA domain.  The general stoichiometry employed to achieve 20% nominal 
crosslinking was 9:2.2:1 for carboxylic acid units : EDCI : crosslinker, and to achieve 
50% nominal crosslinking, the stoichiometry was 3.6:2.2:1. 
General Procedures for GdIII chelation onto DOTAlysine labeled 
micelle/SCKs.  Equivalent amount of GdCl3 was added to the micelle/SCK solutions, 
as an aqueous solution.  The reaction mixtures were then stirred at 60 °C for 6 h.  
After cooling to room temperature, the reaction mixtures were transferred into 
presoaked dialysis tubings (MWCO ca. 6,000-8,000 Da) and exhaustive dialysis 
against nanopure water (pre-treated with chelax) was carried out to remove free GdIII. 
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 Preparation of Gd-DOTAlysine-g-PAA60-b-PS35 Block Copolymers.  Two 
methods were carried out to afford PAA-b-PS, grafted with Gd-coordinated 
DOTAlysine: 
(1) DOTAlysine was grafted onto the amphiphilic block copolymer 
PAA60-b-PS35 by conventional amidation chemistry in organic solvent described 
above, with coupling efficiencies larger than 85%.  After purification by dialysis 
against water and lyophilization, the average numbers of DOTAlysine per polymer 
chain were determined by 1H NMR.  Four different samples were prepared, with the 
average numbers of DOTAlysine per polymer chain being 2.3, 3.0, 3.8 and 8.0.  The 
polymers, DOTAlysine-g-PAA60-b-PS35, were then dissolved in DMF and incubated 
with GdCl3, which was added as a DMF solution.  Dialysis against nanopure water 
was carried out to remove un-coordinated GdIII, Gd-DOTAlysine-g-PAA60-b-PS35 was 
obtained after lyophilization. 
(2) Gd-Coordinated DOTAlysine was prepared first as described as below.  
To a stirred solution of DOTAlysine (23.0 mg, 33.2 μmol) in 8.0 mL of nanopure 
water at ambient temperature was added GdCl3 (8.7 mg, 33 μmol).  The pH of the 
mixture was adjusted to around 7.5 with a dilute NaOH solution.  The mixture was 
allowed to stir for 8 h.  Aliquots of the reaction mixture were removed and Arsenazo 
III (2,2’-(1,8-dihydroxy-3,6-disulfonaphthylene-2,7-bisazo)dibenzenearsonic acid), 
which gives unique UV-vis absorbance spectra (λmax ~650 nm) in the presence of free 
GdIII was used to monitor the progress of the reaction.12-13  More DOTAlysine (0.3 
equivalent, in 3 batches) was added to the reaction mixture until the Arsenazo-III 
indicator tested negative.  The reaction mixture was then lyophilized to afford 
Gd-DOTAlysine as a yellow powder.  
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 Gd-DOTAlysine was grafted to the block copolymer PAA60-b-PS35 by following 
a procedure similar to that used to graft DOTAlysine.  Due to the presence of the 
paramagnetic GdIII, the average number of Gd-DOTAlysine per polymer chain was 
determined by ICP-MS.  One sample, with averagely 1.3 Gd-DOTAlysine per 
polymer chain, was prepared. 
 General Procedures for Micellization of Gd-DOTAlysine-g-PAA61-b-PS34 
and Shell Crosslinking into SCKs.  To a solution of 
Gd-DOTAlysine-g-PAA60-b-PS35 in DMSO (c.a. 1.0 mg/mL), was added dropwise an 
equal volume of nanopure water via a syringe pump over 6 h.  The mixture was 
further stirred for 12 h, followed by dialysis against nanopure water for 4 d to afford a 
clear micelle solution. 
 To a solution of micelle in nanopure water, was added dropwise a solution of 
2,2’-(ethylenedioxy)-bis(ethylamine) (c.a. 1.0 mg/mL) over 10 min.  The reaction 
mixture was stirred for ca. 2 h.  A solution of EDCI 
(1-[3’-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide) in nanopure water 
was to the reaction mixture via a syringe pump over 30 min.  The reaction mixture 
was further stirred for 20 h, followed by dialysis against nanopure water for 4 d, to 
remove all of the impurities and afford the SCK solution. 
 
Conclusions 
 The production of a new type of nanoscale contrast agent for magnetic resonance 
imaging, Gd-DOTAlysine-Micelle/SCKs, has been described.  Methods to afford 
clean nanoscale contrast agents without the contamination of free GdIII ions have been 
developed.  Compared to the small molecule complex, Gd-DOTAlysine, enhanced 
T1 relaxivities were achieved, which was a result from increased rotational correlation 
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time.  It was also found that T1 relaxivities increased as the extent of crosslinking of 
the micelles increased.  With the good blood pool imaging capabilities, and potential 
for active targeting (described in previous chapters), as well as the enhanced T1 
relaxivities, Gd-DOTAlysine functionalized SCKs have the potentials to serve as 
promising candidates for in vivo MRI imaging. 
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Chapter 5 
Peptide-mediated Growth of Silver Nanoparticles with Shell 
Crosslinked Nanoparticles (SCKs) as the Template 
 
Abstract 
In this work, silver nanoparticles were synthesized with polymeric shell crosslinked 
nanoparticles (SCKs) and a metal binding peptide, AG-P35, as the templates.  The 
SCKs possessing an amphiphilic core-shell morphology were prepared from the aqueous 
self assembly of the amphiphilic block copolymer of acrylic acid and methyl acrylate 
(PAA105-b-PMA184) and subsequent crosslinking of the shell domain through amidation 
reaction of 2,2’-(ethylenedioxy)bis-ethylamine with the carboxylic acid groups on the 
micelle.  It was found that both the SCKs and the peptide can influence the growth of 
silver nanoparticles.  Silver nanoparticles of various morphologies, such as dendrite, 
flower-like and plate-like nanoparticles, were obtained by varying the ratios of SCK, 
AG-P35 and silver nitrate.   
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Introduction  
Inorganic nanocrystals have been attracting considerable interests due to their novel 
properties which are strongly influence by their size, shape, surface composition, spatial 
ordering, and interaction with surrounding environments.1  These materials are 
considered to be intriguing functional materials with wide potential applications in 
various fields such as magnetic resonance imaging,2, 3 catalysis,4 electrochemistry,5 
biological labeling,6 optoelectronics,7 photoluminescence8 and surface enhanced Raman 
scattering9, 10. 
Controlling the size of nanocrystals is of particular interest because of the effect 
these parameters have on the observed properties of the nanocrystals.  However, the fact 
that nanoparticles and assemblies exhibit unique electrical, optical, magnetic, and 
catalytic properties is not only because of the dramatic increase in the surface 
area/volume ratio as the particle size is reduced but also because of the emergence of 
collective and nanoscale properties as a result of the interparticle arrangement or 
assembly.11  It is the exploration of such nanostructures that has captured the growing 
interests of research at the interfaces of chemistry, physics, biology, and materials science.  
While many nanoparticles exhibit unique electronic properties different from their bulk 
counterparts, the incorporation of macromolecules into metal or semiconductor 
nanoparticles produces interesting photoinduced charge transfer and separation.12  The 
electrical properties of thin-film assemblies of metal nanoparticles mediated by 
bifunctional mediators have been exploited for chemiresistor sensing,13 where the 
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sorption of volatile organic compounds (VOCs) leads to a change in electron hopping or 
tunneling properties depending upon particle size, interparticle distance, and medium 
properties.  Various macromolecules and their assemblies, such as viruses and 
proteins,14-19 polymers,20, 21 porous polymer matrices,22 microemulsions,23 starch 
vermicelli1 and cellulose,24 have been studied as templates to grow inorganic 
nanoparticles.  Synthetic peptides are also being developed to direct the growth of 
inorganic nanoparticles25-27.  These peptides are designed to bind to certain faces of 
inorganic nanocrystals. 
Among all the metal nanoparticles, silver nanoparticles have been intensively studied 
because of their intriguing optical, electronic, magnetic and mechanical properties.24, 28, 29  
In particular, silver nanoparticles interact with light better than any know chromophore,30 
they also play an important role in antimicrobial activity,31 catalysis32 and facilitated 
olefin transport33. 
In this work, we chose shell crosslinked nanoparticles (SCKs) as the scaffolding and 
template for silver nanoparticle growth.  The peptide, AG-P35 (WSWRSPTPHVVT), 
reported to be able to direct the growth of silver nanocrystals due to its ability to bind the 
(1 1 1) face of silver nanocrystals,27 was selected as the co-template.  SCKs are 
self-assembled core-shell materials, originating from micelles assembled from 
amphiphilic block copolymers that are stabilized through a crosslinking reaction, to 
afford a robust structure of controlled size (10-200 nm).34, 35 This particular work focused 
on SCKs from poly(acrylic acid)-b-poly(methyl acrylate), prepared by the crosslinking of 
the PAA shell domain of the micelle, with a diamino-terminated di-ethylene glycol 
crosslinker.  Growth of silver nanoparticles with various morphologies, such as 
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dendrites, flower-like and layer-structured assemblies, was achieved.  The nanoparticle 
growth was found to be strongly dependent upon stoichiometry and incubation time.  In 
this chapter, the influence of the SCK and the peptide AG-P35 upon the growth of silver 
nanoparticles is discussed.  Silver nanoparticles formed with SCK as the template may 
find potential as a nano-antimicrobial agent.  These SCK nanoparticles derived from 
poly(acrylic acid)-b-poly(methyl acrylate) were found to be both non-toxic to mammalian 
cells and non-immunogenic within mice.36  Additionally, targeting ligands such as folic 
acid and αvβ3 integrin receptors can be easily functionalized onto the shell layer of the 
SCK, as described in previous chapter and also in literature.37 
 
Results and Discussion 
The SCK nanoparticles were prepared from the aqueous assembly of the amphiphilic 
diblock copolymer, poly(acrylic acid)105-b-poly(methyl acrylate)184 (PAA105-b-PMA184), 
and crosslinking of the resultant micellar structure throughout the shell layer.  The 
amphiphilic block copolymer was prepared through sequential atom transfer radical 
polymerization (ATRP) of t-butyl acrylate and methyl acrylate to afford PtBA-b-PMA 
(this polymer was a gift from a former group member, Dr. Zhiyun Chen), followed by 
acidolysis by trifluoacetic acid in dichloromethane to remove the t-butyl ester protecting 
groups.  Through addition of water to the THF solution of the amphiphilic block 
copolymer, micelle was formed.  Covalent crosslinking of the shell domain carboxylic 
acid group of the micelle with 2,2’-(ethylenedioxy)-bis(ethylamine) and 
1-(3′-dimethylaminopropyl)-3-ethylcarbo-diimide methiodide (EDCI) was performed to 
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afford the SCKs.  In this study, a nominally 50% crosslinked SCK was used.  The SCK 
was characterized by DLS (Dh(num) 45 ± 4 nm) and TEM (33 ± 2 nm) (Figure 5-1). 
A B 
B
Fig
Figure 5-1.  A) Particle size distribution from dynamic light scattering (DLS) of the 
SCKs.  B) Transmission electron microscopy (TEM) images of the SCKs. 
 
In general, for silver nanoparticle growth, an aqueous solution of SCKs was 
incubated with AG-P35 for 24 h, followed by the addition of AgNO3 (Scheme 5-1).  
Aliquots of the reaction mixture were taken at different time points and the growth of 
silver nanoparticles was monitored by TEM and SEM.  Experiments with varied ratios 
of polymer/peptide/AgNO3 were performed (Table 5-1). 
Since the peptide AG-P35 was reported to be able to reduce AgNO3 to Ag, no 
reducing agents were introduced when AG-P35 was used.  For the first experiment, 
SCK and AG-P35 were incubated under ambient conditions for 24 h, followed by the 
addition of AgNO3 solution.  Dendritic silver nanoparticles were obtained.  These 
dendritic silver nanoparticles were composed of near-spherical silver nanoparticles with 
TEM diameters around 30 nm, which was similar to that of the SCK nanoparticles.  It.
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was also observed that the size of the dendritic silver nanoparticles increased with 
incubation time (Figure 5-2)  It’s hypothesized that the silver cations are 
immobilized in the shell domain of the SCK, through non-covalent interactions.  
Later reduction affords the silver nanoparticles with TEM diameters around 30-40 nm.  
These silver nanoparticles have strong interactions between each other and tend to 
form aggregates, resulting in a dendritic assembly of the spherical silver nanoparticles.  
The extent of aggregation increases with incubation time, which in turn gives 
increasing sizes. 
As the control experiments, AgNO3 was incubated with SCK/NH2NH2 (exp. 2), 
AG-P35 (exp. 3) and NH2NH2 (exp. 4), respectively (the NH2NH2 here was 
introduced as the reducing agent for the formation of Ag from AgNO3).  For exp. 2 
and exp. 4, the reaction mixtures both turned brown upon the addition of hydrazine, 
indicating the fast reduction of Ag+ by NH2NH2.  Irregularly shaped nanoobjects 
were observed by TEM (Figure 5-2).  No nanoparticles were observed by TEM for 
exp. 4.  
Due to its instability, AgNO3 can decompose and undergo self-redox reaction to 
form elemental silver.  Experiments to grow silver nanoparticles by incubating 
AgNO3 with SCK solutions were performed (exp. 5).  Aliquots of reaction mixtures 
were taken at different time points and analyzed by scanning electron microscopy 
(SEM) and energy dispersive X-Ray (EDX) spectroscopy.  As can be seen from the 
SEM images for exp. 5 (Figure 5-3), nanoparticles with flower-like structure were 
formed almost right upon the mixing of AgNO3 and the SCK solution.  In the first 80 
min, the sizes of these nanoparticles were around 3 μm, and no obvious size 
expansion with incubation time was observed, except that the branches of the 
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nanoparticles were getting thicker.  Larger nanostructures were obtained at 10 h, 
around 7 μm.  For the control experiment without SCK, flower-like nanostructures 
were also observed.  Unlike the nanostructures obtained in the presence of SCK, the 
end of each branch was stretching out towards all directions and formed a fan-like end.  
It’s unknown whether the silver nanoparticles formed in the aqueous solution, or on 
the TEM grids after water was evaporated.  Energy dispersion X-ray microscopy 
(EDX) confirmed that these structures were silver nanoparticles (Figure 5-4).  This 
indicated that the SCKs were acting as the template to form more ordered silver 
nanostructures and that AG-P35 was contributing to the formation of spherical silver 
nanoparticles. 
Dendritic silver nanoparticles were grown when the amounts of silver nitrate, 
SCK and AG-P35 (COOH/AG-P35/AgNO3 = 5.95/0.2/1) were comparable.  The 
growth of silver nanoparticles with high loading of silver nitrate was also studied 
(COOH/AG-P35/AgNO3 = 0.009/0.0004/1, exp. 6).  When AgNO3 was in highly 
excess amount, nanocrystals composed of silver nano-plates were formed (Figure 
5-5).  It’s observed that at the beginning of the crystallization (2 h incubation), no 
obvious silver nano-plates were formed.  After 10 h incubation, highly ordered 
layered structures were formed.  For the control experiment (AgNO3 with the same 
concentration without SCK or Ag-P35), layered structures were also observed, but the 
assembly of the layers were of less order.  Silver nitrate at high concentrations tends 
to form randomly assembled nano-plates.  With the incorporation of SCK and 
AG-P35, non-plate silver nanoparticle was first formed and served as the nucleating 
core for further silver deposition.  Since silver nitrate was in a large excess, highly 
ordered nano-plates assembly was achieved.  
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Experimental Section 
Materials  All solvents were purchased from Sigma-Aldrich and were used without 
further purification unless otherwise noted.  Trifluoroacetic acid (TFA; 95%; Aldrich), 
2,2′-(ethylenedioxy)-bis(ethylamine) (97%; Aldrich), 
1-(3′-dimethylaminopropyl)-3-ethylcarbo-diimide methiodide (EDCI; 98%; Aldrich), 
were used as received.  Supor 25 mm 0.1 μm Spectra/Por Membrane tubes (molecular 
weight cutoff (MWCO) 3,500 or 6-8000 Da), purchased from Spectrum Medical 
Industries Inc., were used for dialysis.  Nanopure water (18 MΩ⋅cm) was acquired by 
means of a Milli-Q water filtration system (Millipore Corp.; Bedford, MA).  Silver 
nitrate (AgNO3, 99.0%) and hydrazine hydrate (NH2NH2⋅H2O, 25% in H2O) were 
purchased from Aldrich.  The peptide, AG-P35 (WSWRSPTPHVVT, 99%), was 
customized from New England Peptide, LLC., MA.  The block copolymer, 
poly(tert-butyl acrylate)105-b-polymer(methyl acrylate)184 (PtBA105-b-PMA184), was 
synthesized by Dr. Zhiyun Chen through sequentially incorporating tert-butyl acrylate 
and methyl acrylate by atom transfer radical polymerization (ATRP) procedures.  The 
PtBA segment was later converted into poly(acrylic acid) (PAA) block through acidolysis 
by TFA. 
Instrumental 
 1H NMR spectra were recorded on a Varian 300 MHz spectrometer interfaced to a 
UNIX computer using Mercury software.  Chemical shifts are referred to the solvent 
proton resonance.  Infrared spectra were acquired on a Perkin-Elmer Spectrum BX 
FT-IR instrument using KBr pellets. 
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 Differential scanning calorimetry (DSC) measurements were performed with a 
DSC822e instrument (Mettler-Toledo, Inc.) in a temperature range of – 100 to 180 °C 
with a ramp rate of 10 °C/min under nitrogen.  Data were acquired and analyzed using 
STARe software (Mettler-Toledo, Inc.).  The glass transition temperature, Tg, was 
determined at the midpoint of the inflection tangent upon the third heating scan. 
 Hydrodynamic diameters (Dh) and size distributions for the SCKs in aqueous 
solutions were determined by dynamic light scattering (DLS).  The DLS instrument 
consisted of a Brookhaven Instruments Limited (Worcestershire, U.K.) system, including 
a model BI-200SM goniometer, a model BI-9000AT digital correlator, a model 
EMI-9865 photomultiplier, and a model 95-2 Ar ion laser (Lexel Corp., Farmindale, NY) 
operated at 514.5 nm.  Measurements were made at 20 °C.  Prior to analysis, solutions 
were filtered through a 0.22 μm Millex GV PVDF membrane filter (Millipore Corp., 
Medford, MA) and then centrifuged in a model 5414 microfuge (Brinkman Instruments, 
Inc., Westbury, NY) for 10 minutes to remove dust particles.  Scattered light was 
collected at a fixed angle of 90 °.  The digital correlator was operated with 522 ratio 
spaced channels, and initial delay of 5 μs, a final delay of 100 ms, and a duration of 10 
minutes.  A photomultiplier aperture of 400 μm was used, and the incident laser 
intensity was adjusted to obtain a photon counting of between 200 and 300 kcps.  Only 
measurements in which the measured and calculated baselines of the intensity 
autocorrelation function agreed to within 0.1% were used to calculate particle sizes.  
The calculations of the particle size distributions and distribution averages were 
performed with the ISDA software package (Brookhaven Instruments Company), which 
employed single-exponential fitting, cumulants analysis, non-negatively constrained 
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least-squares (NNLS) and CONTIN particle size distribution analysis routines.  All 
determinations were made in triplicate. 
 Transmission electron microscopy (TEM) was performed in bright-field mode with a 
JEOL 2000-FX at 150 kV accelerating voltage.  Micelle/SCK nanoparticle samples for 
TEM measurements were diluted with 1 wt% of phosphotungstic acid (PTA) stain 
solution (v/v, 1:1).  No stain was used for silver nanoparticle samples.  Carbon grids 
(Ted Pella, Inc., Redding, CA) were exposed to oxygen plasma treatment to increase the 
surface hydrophilicity.  Micrographs were collected at 100,000 magnifications.  The 
number average particle diameters (Dav) and standard deviations were generated from the 
analysis of a minimum of 150 particles from at least three different micrographs.  TEM 
was performed by Mr. G. Mike Veith. 
 Scanning electron microscopy (SEM) measurements were performed on a field 
emission scanning electron microscope (Hitachi s-4500), equipped with a NORAM 
Instruments energy dispersive X-Ray (EDX) microanalysis system, a back scattering 
detector, and a mechanical straining stage.  Samples for SEM measurements were 
dropped onto TEM grids (5 μL), and allowed to dry under ambient conditions. 
 
Preparation of poly(acrylic acid)-b-poly(methyl acrylate) PAA-b-PMA.  To a 100 
mL round-bottom flask equipped with a stir bar was added the block copolymer 
PtBA105-b-PMA184 (1.20 g, 0.041 mmol (polymer), 4.27 mmol (t-butyl ester)) and 25 mL 
of dichloromethane.  To the solution was then added dropwise trifluoacetic acid (TFA) 
(10 mL, 130 mmol).  The reaction mixture was allowed to stir at room temperature 
overnight.  The solvent was removed under reduced pressure and the resultant polymer 
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was re-dissolved in THF, transferred to presoaked dialysis tubing (MWCO 6-8000 Da) 
and dialyzed against nanopure water.  The resulting aqueous solution was lyophilized to 
afford a white powder.  Yield: 0.90 g (94%).  (Tg)PAA = 134 °C.  (Tg)PMA = 13 °C.  
FTIR(cm-1): 3500-2700, 1730, 1601, 1493, 1452, 1392, 1368, 1259, 1164, 846, 757, 704, 
542.  1H NMR (DMSO-d6, 300 MHz, ppm): δ 11.9-12.5 (br, COOH), 3.52-3.65 (br, 
CH3O), 2.15-2.40 (br, CH of the polymer backbone) 1.30-1.90 (br, CH2 of the polymer 
backbone).  13C NMR (DMSO-d6, 75 MHz, ppm): δ 176.0, 174.5, 80.5, 51.6, 34.0-35.0, 
15.0. 
Preparation of PAA-b-PMA micelle.  To a 250 round-bottom flask equipped with a 
stir bar was added the amphiphilic block copolymer (100 mg) and tetrahydrofuran (100 
mL) to afford a 1.00 mg/mL solution.  After stirring for 2 h, 100 mL of nanopure water 
was added dropwise via a syringe pump over 6 h.  The mixture was further stirred for 12 
h, followed by dialysis against nanopure water in MWCO 6-8000 Da dialysis tubing for 4 
d to afford a clear micelle solution (0.510 mg/mL).  Dh(num) = 51 ± 4 nm. 
Preparation of PAA-b-PMA SCKs.  To a solution of micelle in nanopure water (0.269 
mmol COOH), was added dropwise a solution of 2,2’-(ethylenedioxy)-bis(ethylamine) 
(c.a. 1.0 mg/mL, 0.0672 mmol) over 10 min.  The reaction mixture was stirred for c.a. 2 
h.  A solution of EDCI (1-[3’-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide) 
in nanopure water (2 mg/mL, 0.134 mmol) was to the reaction mixture via a syringe 
pump over 30 min.  The reaction mixture was further stirred for 20 h, followed by 
dialysis against nanopure water for 4 days in MWCO 6-8000 Da dialysis tubing, to 
remove all of the impurities and afford the SCK solution (0.240 mg/mL).  Dh(num) = 45 
± 4 nm.  DTEM = 25 ± 2 nm. 
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General Procedure for the Preparation of Silver Nanoparticles.  AgNO3 solution 
(aqueous, 30 mM), SCK, and the peptide solution (aqueous, 0.20 mg/mL) were incubated 
at ambient conditions with varied ratios.  Aliquots of the mixture were taken for 
TEM/SEM measurements. 
 
Conclusions 
We have shown here the synthesis of silver nanoparticles by use of shell crosslinked 
nanoparticles and the surface binding peptide (AG-P35) as the templates.  At low silver 
nitrate concentrations, dendritic silver nanoparticles (1-10 μm) consisting of nearly 
spherical silver nanoparticles (~ 30 nm) were formed in the presence of SCK and the 
peptide AG-P35.  Without AG-P35, flower-like silver nanoparticles were obtained in 
the presence of SCKs.  Self-assembled silver nano-plates were formed at high silver 
nitrate concentrations.  Silver nanoparticles were also formed from aqueous silver 
nitrate solution, without the use of either SCK or AG-P35.  Whether the silver 
nanoparticles formed in aqueous solution, or on the TEM grids after water evaporation 
remains unknown.  At higher silver nitrate concentrations, silver nano-assembly consists 
of nano-plates were formed.  The presence of the SCKs and AG-P35 contributed to a 
higher degree of order compared to the nano-plate structures obtained from AgNO3 only. 
 
Acknowledgments 
The author thank Dr. Zhiyun Chen for providing the block copolymer, PtBA105-b-PMA184, 
Mr. G. Mike Veith for TEM imaging, Mr. Lawrence Norcio for SEM training and the 
Department of Energy, Environmental & Chemical Engineering at Washington 
144
University in Saint Louis for use of SEM/EDX facilities.  This material is based upon 
work supported by the National Science Foundation (DMR-0210247). 
References 
 
1. Chairam, S.; Poolperm, C.; Somsook, E., Starch vermicelli template-assisted 
synthesis of size/shape-controlled nanoparticles. Carbohydr. Polym. 2009, 75 (4), 
694-704. 
2. Berret, J. F.; Sandre, O.; Mauger, A., Size Distribution of Superparamagnetic 
Particles Determined by Magnetic Sedimentation. Langmuir 2007, 23 (6), 2993-2999. 
3. Berret, J.-F.; Schonbeck, N.; Gazeau, F.; El Kharrat, D.; Sandre, O.; Vacher, A.; 
Airiau, M., Controlled Clustering of Superparamagnetic Nanoparticles Using Block 
Copolymers: Design of New Contrast Agents for Magnetic Resonance Imaging. J. Am. 
Chem. Soc. 2006, 128 (5), 1755-1761. 
4. Lewis, L. N., Chemical catalysis by colloids and clusters. Chem. Rev. 1993, 93 (8), 
2693-2730. 
5. Wang, J.; Liu, G.; Engelhard, M. H.; Lin, Y., Sensitive Immunoassay of a Biomarker 
Tumor Necrosis Factor-&#x03B1; Based on Poly(guanine)-Functionalized Silica 
Nanoparticle Label. Anal. Chem. 2006, 78 (19), 6974-6979. 
6. Nicewarner-Pena, S. R.; Freeman, R. G.; Reiss, B. D.; He, L.; Pena, D. J.; Walton, I. 
D.; Cromer, R.; Keating, C. D.; Natan, M. J., Submicrometer Metallic Barcodes. Science 
2001, 294 (5540), 137-141. 
7. Kamat, P. V., Photophysical, Photochemical and Photocatalytic Aspects of Metal 
Nanoparticles. J. Phys. Chem. B 2002, 106 (32), 7729-7744. 
145
8. Yuwono, A. H.; Zhang, Y.; Wang, J.; Zhang, X. H.; Fan, H.; Ji, W., Diblock 
Copolymer Templated Nanohybrid Thin Films of Highly Ordered TiO2 Nanoparticle 
Arrays in PMMA Matrix. Chem. Mater. 2006, 18 (25), 5876-5889. 
9. Nie, S.; Emory, S. R., Probing Single Molecules and Single Nanoparticles by 
Surface-Enhanced Raman Scattering. Science 1997, 275 (5303), 1102-1106. 
10. Dick, L. A.; McFarland, A. D.; Haynes, C. L.; Van Duyne, R. P., Metal Film over 
Nanosphere (MFON) Electrodes for Surface-Enhanced Raman Spectroscopy 
(SERS):&nbsp; Improvements in Surface Nanostructure Stability and Suppression of 
Irreversible Loss. J. Phys. Chem. B 2002, 106 (4), 853-860. 
11. Sudeep, P. K.; Ipe, B. I.; Thomas, K. G.; George, M. V.; Barazzouk, S.; Hotchandani, 
S.; Kamat, P. V., Fullerene-Functionalized Gold Nanoparticles. A Self-Assembled 
Photoactive Antenna-Metal Nanocore Assembly. Nano Lett. 2002, 2 (1), 29-35. 
12. Elim, H. I.; Ji, W.; Yuwono, A. H.; Xue, J. M.; Wang, J., Ultrafast optical 
nonlinearity in poly(methylmethacrylate)-TiO2 nanocomposites. Appl. Phys. Lett. 2003, 
82 (16), 2691. 
13. Park, B. J.; Sung, J. H.; Kim, K. S.; Chin, I.; Choi, H. J., Preparation and 
Characterization of Poly(Methyl Methacrylate) Coated TiO2 Nanoparticles. Journal of 
Macromolecular Science: Physics 2006, 45 (1), 53-60. 
14. Flynn, C. E.; Lee, S.-W.; Peelle, B. R.; Belcher, A. M., Viruses as vehicles for 
growth, organization and assembly of materials. Acta Mater. 2003, 51 (19), 5867-5880. 
15. Mao, C.; Solis, D. J.; Reiss, B. D.; Kottmann, S. T.; Sweeney, R. Y.; Hayhurst, A.; 
Georgiou, G.; Iverson, B.; Belcher, A. M., Virus-Based Toolkit for the Directed 
146
Synthesis of Magnetic and Semiconducting Nanowires. Science 2004, 303 (5655), 
213-217. 
16. Lee, S.-W.; Mao, C.; Flynn, C. E.; Belcher, A. M., Ordering of Quantum Dots Using 
Genetically Engineered Viruses. Science 2002, 296 (5569), 892-895. 
17. T. Douglas, E. S. D. W. A. A. M. L. M. Y., Protein Engineering of a Viral Cage for 
Constrained Nanomaterials Synthesis. Adv. Mater. 2002, 14 (6), 415-418. 
18. Kroger, N.; Deutzmann, R.; Sumper, M., Polycationic Peptides from Diatom 
Biosilica That Direct Silica Nanosphere Formation. Science 1999, 286 (5442), 
1129-1132. 
19. Brott, L. L.; Naik, R. R.; Pikas, D. J.; Kirkpatrick, S. M.; Tomlin, D. W.; Whitlock, P. 
W.; Clarson, S. J.; Stone, M. O., Ultrafast holographic nanopatterning of biocatalytically 
formed silica. Nature 2001, 413 (6853), 291-293. 
20. Sun, Y.; Xia, Y., Shape-Controlled Synthesis of Gold and Silver Nanoparticles. 
Science 2002, 298 (5601), 2176-2179. 
21. Kyung Ju Lee, J. T. P. J. H. G. J. H. K., Synthesis of amphiphilic graft copolymer 
brush and its use as template film for the preparation of silver nanoparticles. J. Polym. 
Sci., Part A: Polym. Chem. 2008, 46 (12), 3911-3918. 
22. Rifai, S.; Breen, C. A.; Solis, D. J.; Swager, T. M., Facile in Situ Silver Nanoparticle 
Formation in Insulating Porous Polymer Matrices. Chem. Mater. 2006, 18 (1), 21-25. 
23. Andersson, M.; Pedersen, J. S.; Palmqvist, A. E. C., Silver Nanoparticle Formation 
in Microemulsions Acting Both as Template and Reducing Agent. Langmuir 2005, 21 
(24), 11387-11396. 
147
24. He, J.; Kunitake, T.; Watanabe, T., Porous and nonporous Ag nanostructures 
fabricated using cellulose fiber as a template. Chem. Commun. 2005, (6), 795-796. 
25. Hartgerink, J. D.; Beniash, E.; Stupp, S. I., Self-Assembly and Mineralization of 
Peptide-Amphiphile Nanofibers. Science 2001, 294 (5547), 1684-1688. 
26. Naik, R. R.; Stringer, S. J.; Agarwal, G.; Jones, S. E.; Stone, M. O., Biomimetic 
synthesis and patterning of silver nanoparticles. Nat. Mater. 2002, 1 (3), 169-172. 
27. Naik, R. R.; Jones, S. E.; Murray, C. J.; McAuliffe, J. C.; Vaia, R. A.; Stone, M. O., 
Peptide Templates for Nanoparticle Synthesis Derived from Polymerase Chain 
Reaction-Driven Phage Display. Adv. Funct. Mater. 2004, 14 (1), 25-30. 
28. He, J.; Kunitake, T., Formation of Silver Nanoparticles and Nanocraters on Silicon 
Wafers. Langmuir 2006, 22 (18), 7881-7884. 
29. Deshmukh, R. D.; Composto, R. J., Surface Segregation and Formation of Silver 
Nanoparticles Created In situ in Poly(methyl Methacrylate) Films. Chem. Mater. 2007, 
19 (4), 745-754. 
30. Evanoff, D. D.; Chumanov, G., Size-Controlled Synthesis of Nanoparticles. 2. 
Measurement of Extinction, Scattering, and Absorption Cross Sections. J. Phys. Chem. B 
2004, 108 (37), 13957-13962. 
31. Balogh, L.; Swanson, D. R.; Tomalia, D. A.; Hagnauer, G. L.; McManus, A. T., 
Dendrimer-Silver Complexes and Nanocomposites as Antimicrobial Agents. Nano Lett. 
2001, 1 (1), 18-21. 
32. Jana, N. R.; Sau, T. K.; Pal, T., Growing Small Silver Particle as Redox Catalyst. J. 
Phys. Chem. B 1999, 103 (1), 115-121. 
148
33. Kang, Y. S.; Kang, S. W.; Kim, H.; Kim, J. H.; Won, J.; Kim, C. K.; Char, K., 
Interaction with Olefins of the Partially Polarized Surface of Silver Nanoparticles 
Activated by p-Benzoquinone and Its Implications for Facilitated Olefin Transport. Adv. 
Mater. 2007, 19 (3), 475-479. 
34. Thurmond, K. B.; Kowalewski, T.; Wooley, K. L., Water-Soluble Knedel-like 
Structures: The Preparation of Shell-Cross-Linked Small Particles. J. Am. Chem. Soc. 
1996, 118 (30), 7239-7240. 
35. Butun, V.; Billingham, N. C.; Armes, S. P., Synthesis of Shell Cross-Linked Micelles 
with Tunable Hydrophilic/Hydrophobic Cores. J. Am. Chem. Soc. 1998, 120 (46), 
12135-12136. 
36. Becker, M. L.; Bailey, L. O.; Wooley, K. L., Peptide-Derivatized Shell-Cross-Linked 
Nanoparticles. 2. Biocompatibility Evaluation. Bioconjugate Chem. 2004, 15 (4), 
710-717. 
37. Pan, D.; Turner, J. L.; Wooley, K. L., Shell Cross-Linked Nanoparticles Designed To 
Target Angiogenic Blood Vessels via αvβ3 Receptor-Ligand Interactions. 
Macromolecules 2004, 37 (19), 7109-7115. 
 
 
149
 
 
Chapter 6 
 
Conclusion 
 
Two types of polymeric nanoparticles, SCKs based on PAA-b-PS, and micelle from 
a hyperbranched star-like amphiphilic poly(acrylic acid)-b-poly(trifluomethyl 
methacrylate), have been studied as potential diagnosic and therapeutic delivery agents.   
Methods have been optimized to develop shell crosslinked nanoparticles bearing 
cyclic KCRGDC peptide as the nanoscale antagonist to αvβ3 integrin, for treatment with 
acute vascular injuries.  Nanoparticles based on PAA-b-PS system, labeled with 
KCRGDC prepared from post-labeling the 5-FAM-KCRGDC peptide onto micelle/SCKs 
assembled from HOOC-PEG30004.0-g-DOTAlysine3.2-g-PAA58.8-b-PS71 showed 
significantly improved IC50 values to αvβ3 than those nanoparticles prepared from 
pre-labeling the NH2-PEG5000-5-FAM-KCRGDC to amphiphilic PAA-b-PS block 
copolymers.  It’s hypothesized that when the NH2-PEG5000-5-FAM-KCRGDC was 
pre-attached to the polymer, the majority of the peptide is buried underneath the shell 
layer during the course of self-assembly, leading to low accessibility to bind to outer 
integrins.  All the RGD-labeled nanoparticles showed strong specific binding to U87MG 
glioma cells.  A cell-based assay provides further information on binding affinity as well 
as internalization of these nanoparticles constructs  Despite the fact that the 
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nanoparticles prepared by the post-labeling method having the best IC50 values to αvβ3, 
they were less internalized into U87MG glioma cells and showed weaker binding.  This 
discrepancy can be explained by the fact that the isolated integrin binding assay has a 
constrained geometry and lacks many components found in vivo.  With the good cell 
targeting capabilities, good biodistribution been reported, as well as with the 
DOTAlysine acting as the chelator of radio metals for imaging for PET imaging, these 
nanoparticles possess good potential to be developed into nanoscale diagnostic and 
therapeutic agent delivery vehicles.  
To the hyperbranched star-like amphiphilic poly(acrylic acid)-b-poly(trifluomethyl 
methacrylate), an F3 peptide, which specifically targets to nucleolin overexpressed in 
many types of cancer tumor domains, was attached through amidation chemistry in 
organic solvents.  Cascade blue (CB) was also attached to the polymer for imaging 
purposes by fluorescence.  Dialysis of the DMF solutions of  the F3 and CB-labeled 
polymers against water afforded the micelles.  Doxorubicin (DOX), a drug widely used 
in chemotherapy treatments for several types of cancer, such as hematological 
malignancies and soft tissue sarcomas, was loaded into the core domain.  In vitro studies 
showed the enhanced binding/targeting as a result of the introduction of F3 peptide.  In 
vivo studies with U87MG mice have shown the ability of these micelles to pass the 
blood-brain barrier and concentrated in the tumor regions.  PEGylation was found to 
enhance the biodistribution of these micelles.  Although the DOX release appeared to be 
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troublesome at this point, this system showed potential to not only provide a novel 
approach to efficiently deliver therapeutics to the targeted tumor site, it can also 
potentially attenuate systemic side effects caused by free doxorubicin. 
Besides functioning as delivery vehicles, SCK nanoparticles prepared from 
PAA-b-PS have also been studied as nanoscale contrast agents for magnetic resonance 
imaging, by anchoring a gadolinium complex of DOTAlysine onto the nanoparticles.  
Methods to achieve clean nanoscale contrast agents (i.e. with no free or loosely bound 
Gd3+ ions) were developed.  As expected, compared to the Gd-DOTAlysine small 
molecule, enhanced relaxivities were achieved by conjugating the small molecule onto 
SCKs, due to the decreased tumbling rate of the nanoparticles.  The relaxivities were 
found to be increasing with the extents of crosslinking.  A reasonable explanation for 
this is that higher extents of crosslinking makes the environment of Gd-DOTAlysine 
bound on the SCKs more rigid so that longer rotational correlation time is achieved.  
With the good blood pool imaging capabilities, and potential for active targeting, as well 
as the enhanced T1 relaxivities, SCKs have the potential to serve as a promising candidate 
for in vivo MRI imaging. 
Finally, SCKs prepared from poly(acrylic acid)-b-poly(methyl acrylate) have been 
studied as the template to synthesize silver nanoparticles, with silver nitrate as the silver 
source.  The peptide, AG-P35, which binds to the (111) face of silver crystals, was used 
as a co-templating molecule.  The morphology of the silver nanoparticle obtained was 
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highly dependent on the reaction conditions, such as concentration ratios, reaction 
durations.  At low silver nitrate concentrations, dendritic silver nanoparticles (1-10 μm) 
consisting of nearly spherical silver nanoparticles (~ 30 nm) were formed in the presence 
of SCK and the peptide AG-P35.  Without AG-P35, flower-like silver nanoparticles 
were obtained in the presence of SCKs.  Self-assembled silver nano-plates were formed 
at high silver nitrate concentrations.  Silver nanoparticles were also formed from 
aqueous silver nitrate solution, without the use of either SCK or AG-P35.  Whether the 
silver nanoparticles formed in aqueous solution, or on the TEM grids after water 
evaporation remains unknown.  At higher silver nitrate concentrations, silver 
nano-assembly consists of nano-plates were formed.  The presence of the SCKs and 
AG-P35 contributed to a higher degree of order compared to the nano-plate structures 
obtained from AgNO3 only. 
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1H NMR, 300 MHz, CD2Cl2
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1H NMR, 300 MHz, DMSO-d6
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Standard curve of 5-FAM-KCRGDC in 5 mM PBS, pH ~ 7.4.
* For simplicity, the disulfide bond connecting the two cysteines was not shown
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